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Abstract
Class II P-glycoprotein (Pgp2) is a plasma membrane protein associated with 
multidrug resistance. This protein and its corresponding mRNA are over expressed in many 
tumours, including liver tumours. Pgp2 has also been found to be overexpressed in all 
models of rat and mouse liver carcinogenesis. Over expression of Pgp2 in liver tumours is 
predominantly due to an increase in stability of Pgp2 mRNA. The main objective of this 
thesis was to compare the degradation pathway of rat Pgp2 mRNA in normal liver and liver 
tumours, with the goal of understanding why Pgp2 is more stable in liver tumours compared 
to normal liver. Considerable effort was spent developing the Yeast Poly (A) tailing RT- 
PCR method in the hope of identifying Pgp2 mRNA degradation product(s) in vivo. This 
study concluded that although in-vitro transcribed RNA can be detected, the Yeast Poly (A) 
tailing RT-PCR method is not suitable for detecting in vivo mRNA degradation product(s). 
This study has introduced key issues related to Pgp2 mRNA that were previously unknown. 
Primer extension identified that endonucleolytic pathway is at least one mechanism for 
degradation of Pgp2 mRNA in vivo. However, the presence of an endonucleolytic cleaved 
product in normal liver and liver tumour suggests that endonucleolytic decay is unlikely to 
contribute to increased stability of Pgp2 mRNA in liver tumours. In summary, the work 
presented in this thesis does not provide answers as to why Pgp2 mRNA is more stable in 
liver tumours in comparison with normal liver. It does, however, enhance our knowledge 
regarding the molecular mechanisms occurring during the processing of Pgp2 mRNA in liver 
tumours and normal liver.
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Chapter 1 
INTRODUCTION
I.O Multidrug Resistance and P-glycoprotein
1.0.1 Overview of Mechanisms Related to Multidrug Resistance
Chemotherapy is the major form of treatment for many types of human cancers and 
involves the administration of various anticancer drugs that target various mechanisms 
related to the growth and development of cancer cells. Alkylating agents are drugs which act 
to covalently bond to intracellular macromolecules causing cross-linking of DNA strands 
thereby increasing cytotoxicity in cells. Antimetabolites are drugs that interfere with normal 
cellular function through inhibition of the formation of normal nucleotides or prevent normal 
cell division from occurring. Natural products which have been found to interfere with 
topoisomerase I and topoisomerase II, bind directly with DNA, and interfere with 
microtubules. Other drugs that are used in chemotherapy include cisplatin and carboplatin, 
which bind to DNA and produce interstrand crosslinks and adducts; hydroxyurea, which 
inhibits DNA synthesis; and L-asparaginase, that causes the degradation of the amino acid L- 
asparagine required for the viability of tumour cells (Tannock and Hill, 1998). The success 
of these agents is often hindered by the fact that majorities of cancers are resistant to 
chemotherapy or develop resistance towards the chemotherapeutic drugs during treatment 
(Chen and Simon, 2000). After exposure to only a few agents cancer cells can become 
resistant to many drugs of diverse mechanisms and structures. This phenomenon is termed 
multidrug resistance (MDR) (Chen and Simon, 2000).
There are many different mechanisms in which drug resistance can occur 
(summarized in Table 1.1.). One mechanism involves the impairment of drug influx. Drug
uptake can occur through passive diffusion, facilitated diffusion, and active transport. All 
three mechanisms allow for drug entry into cells down a concentration gradient, and active 
transport can also lead to transport against a concentration gradient. The development of 
drug resistance involves impairment of unidirectional drug influx, reduced binding affinity of 
the transport carrier for drug, reduced number of transport sites, and slower carrier mobility 
(Tannock and Hill, 1998).
Table 1.1. General mechanisms associated with multidrug resistance (modified from Tannock and Hill, 
1998)
Mechansim Drugs
Decreased Influx Alkylating agents, antimetabolites, cisplatin
Increased efflux by increased expression of ATP 
binding cassette transport proteins or decreased 
expression o f topoisom erase II
Natural products
Increase or decrease in levels o f target enzymes Antimetabolites, natural products
Alterations in target enzymes Antimetabolites, Natural products
Inactivation by glutathione Alkylating agents, natural products, cisplatin
Increased DNA repair Alkylating agents, natural products, cisplatin.
Deceased ability to undergo apoptosis Alkylating agents, natural products, cisplatin.
DNA topoisomerases have also been linked with the development of multidrug 
resistance. Topoisomerases are enzymes that catalyze topologic changes of DNA structure 
required for replication and recombination of DNA and for transcription of RNA. These 
enzymes also play a role in chromosome structure, condensation/decondensation, and 
segregation. Type I topoisomerases facilitate DNA strand unwinding by passing a single 
stranded DNA molecule through a strand break in the complementary strand. Type II 
topoisomerases aid in untwisting of the DNA molecule by catalyzing the passage of double­
stranded DNA molecules through double- strand breaks. Topoisomerases serve as targets for 
chemotherapeutic agents, which seem to stabilize the DNA-enzyme complex, leading to an 
increase in DNA strand cleavage, thereby increasing DNA damage and ultimately cell death. 
Down regulation of both types of topoisomerases, and the production of mutant type I 
topoisomerase have been reported in drug resistant cells (Tannock and Hill, 1998).
Glutathione-s-transferase (GST), has also been reported to play a role in the 
development of multidrug resistance. GST is a widespread enzyme involved in the 
detoxification and protection of normal tissue. Reduced forms of glutathione can inactivate 
peroxides and free radicals produced by some drugs. They can also bind to positively 
charged electrophilic molecules rendering them less noxious and easily excretable. Drugs 
conjugated to reduced forms of glutathione are expelled from cells by the GS-X pump, which 
has a broad specificity for several anticancer drugs. This function is in part reliant on the 
multidrug resistance protein (MRP) (Borst and Elferink, 2002), therefore drug resistance due 
to an increase in expression of MRP most likely depends on GSH-mediated conjugation of 
anticancer drugs (Tannock and Hill, 1998).
DNA repair mechanisms also are involved in drug resistance by enhanced removal of 
DNA adducts and/or crosslinks from resistant strains. Alkylating agents produce DNA 
lesions that may be repaired by three mechanisms: damage reversal; nucleotide excision 
repair; and recombination or complementation. 0^-alkylguanine DNA alkyl transferase 
(AGAT) and 3-methyl-adenine DNA glycosylase are two enzymes involved in DNA repair, 
and both have been reported to be increased in tumour cells resistant to chemotherapeutic 
agents (Tannock and Hill, 1998).
MDR has also been shown to be associated with an important biological process 
termed apoptosis. Apoptosis is a process where intracellular signals trigger sequential events 
leading to cellular death. This complex pathway is regulated by many proteins. Mutation of 
important genes in tumour cells such as p53, responsible for the stimulation of apoptosis, 
may inhibit apoptosis. There is also evidence that some tumours exhibit an increase in bcl-2.
a gene that inhibits apoptosis, and a decrease in bax, a stimulator of apoptosis. Decreased 
apoptosis in tumour cells may then lead to drug resistance (Tannoek and Hill, 1998)
1.0.2 ABC Transporters and Multidrug Resistance
The best identified actions of multidrug resistance are related to active transport 
proteins that belong to the ATP-binding cassette (ABC) superfamily (Ruth et al., 2000). This 
superfamily consists of membrane transporters in yeast, bacteria, parasites, nematodes, 
plants, and mammals. In mammals, this family includes transporters for bile acids, acylated 
fatty acids, chloride ions, peptides, and other substrates (Julien and Gros, 2000). ABC 
transporters play a crueial role in protecting vital bodily structures such as the brain, the 
testis, the cerebrospinal fluid, and the fetus against the uptake of toxic agents, like food 
derivatives and drugs into the body (Borst and Elferink, 2002). They have also been 
associated with many human diseases, ineluding cancer (Gottesman and Ambudkar, 2001). 
There are four plasma membrane proteins belonging to the ABC superfamily associated with 
multidrug resistance; multi-drug resistance protein (Cole et ah, 1992), lung-resistance protein 
(Tannock and Hill, 1998), breast cancer resistanee protein (Doyle et ah, 1998), and P- 
glycoprotein (Ling, 1974) (to be discussed in detail in section 1.0.3).
Multidrug-resistance Protein (MRP) is a glutathione-X conjugate pump and was first 
diseovered in human lung caneer cells exhibiting multidrug resistance (Cole et ah, 1992). 
The discovery of MRP has led to the characterization of 6 related proteins, all involved in the 
transport of anticancer eompounds (Gottesman, 2002). The MRPs identified thus far differ 
in substrate specifieity, tissue distribution, and intracellular location (Borst and Elferink, 
2002). All of the MRPs have been associated with MDR, however, there is yet to be direct
evidence implieating MRPs as the root cause of the development of MDR phenotype in 
human eaneers.
A second protein that is associated with resistance to a wide spectrum of drugs is 
called lung-resistance protein (LRP). This protein is expressed on intraeellular organelles 
known as vaults, whieh are multisubunit structures involved in nueleocytoplasmie transport. 
It has been hypothesized that LRP is involved in eausing drug resistanee by pumping the 
drugs into the vaults, whieh are then exported from the cell (Tannoek and Hill, 1998).
Breast cancer resistant protein (BCRP) is a plasma membrane protein located in the 
apical membranes of placental syneytiotrophoblasts, the epithelial lining of the small 
intestine and colon, hepatoeytes, and the duets and lobules of the mammary gland (Borst and 
Elferink, 2002), and has also been associated with multidrug resistanee. The highest 
concentration of BCRP RNA has been found in the placenta suggesting that this protein has 
an important defense function by preventing entry of the drug to the fetus. Clinically, BCRP 
has been identified to be overproduced in MCF7 breast cancer cells and has shown to have 
high mitoxantrone resistance. Possible inhibitors of BCRP include fumitremorgin C and its 
analogs (Borst and Elferink, 2002).
1.0.3 P-glycoprotein
The first discovered and the only ABC transporter to date shown to be linked with 
development of clinical MDR is P-glyeoprotein (Juliano and Ling, 1976). P-glycoprotein 
(Pgp) is synthesized in the endoplasmic reticulum, and modified in the golgi apparatus 
yielding a glycosylated 170 kDa transmembrane protein. Pgp is found on the luminal surface 
of epithelial cells in various regions of the body such as the large and small intestine, the 
biliary canalicular membranes of hepatoeytes, the apical surface of epithelial cells of the
proximal cells of the kidney, the blood tissue barriers of the testis and brain, the liver, and the 
epithelia of the choroid plexus, (Loo and Clarke, 1999). It has been proposed that Pgp 
functions in several different aspects of normal physiology, such as protection from 
xenobiotics, resistance to apoptosis, intracellular tracking of sterols, and migration of 
dendritic cells into lymphatic vessels (Luker et al., 2000). As well as offering protection, 
Pgp has been associated with the transport of molecules across cell membranes (Brown, 
Thorgeirsson, and Silverman, 1993). These molecules include chemotherapeutic drugs, 
calcium channel blockers, steroid hormones, immunosuppressive agents, and peptide 
antibiotics (Hrycyna et al., 1998). Pgp is a 1280 amino acid polypeptide containing two 
tandem repeats of 610 amino acids, joined by a linker region of 60 amino acids (Loo and 
Clarke, 1999). It is comprised of two homologous halves, with each half spanning the 
plasma membrane bilayer six times (Hrycyna et al., 1998). Each halve of Pgp includes a 
hydrophobic domain with six transmembrane segments and a nucleotide binding ABC 
domain (Ruth et al. 2000). This domain arrangement is characteristic of the ABC superfamily 
(Figure 1.1.) (Loo and Clarke, 1999).
Two classes of Pgp genes exist in humans, class I (Pgpl) and class III (Pgp3). Class I 
(PgpI) is capable of transporting many chemotherapeutic drugs and is associated with 
multidrug resistance (Lee, Bradley & Ling, 1998). Class III (Pgp3), which is not associated 
with multidrug resistance, is known to be a phospholipid translocase abundant in the liver 
(Romsicki and Sharom, 2001). There are three rodent isoforms, class I, class II, and class III. 
Class I and II are associated with the development of multidrug resistance, and class III, 
found to be most abundant in the liver is necessary for transport of phospholipids (Lee, 
Bradley & Ling, 1998). The MDR gene that codes for Pgp in rats is highly conserved with
the MDR gene that codes for Pgp in humans (Table 1.1). For example, rat Pgp2 is 79.1 %
homologous to human Pgpl, and 71.5% homologous to human Pgp3 (Silverman, et al.,
1991).
ATP
ATP
Figure 1.1. Basic structure of P-glycoprotein (modified from Tannock and Hill, 1998).
Table 1.2. Summary of human and rodent P-glycoprotein gene homology, (modified from Silverman et 
al., 1991).
Genes Human Pgpl Human Pgp3
% Homology % Homology
Rat Pgp2 79.1 71.5
Hamster Pgp2 75.7 47.7
Hamster Pgpl 83.5 64.2
Mouse Pgp3 71.1 86.1
Mouse Pgp2 78.7 70.6
Mouse Pgpl 82.2 71.6
Multidmg resistance conferred by overexpression of P-glyeoprotein (Pgp) is one of 
the best-charaeterized forms of resistanee mediated by transport molecules (Luker et al., 
1997). When overexpressed, Pgp funetions to confer multidrug resistance (Loo & Clarke, 
1999) by acting as an ATP-dependant efflux pump that transports drugs with cytotoxic 
activity out of cells before they reaeh intracellular target (Taguchi et al., 1997). These drugs 
include many natural product derived anticancer agents such as doxorubicin, daunorubicin, 
vinblastin, vincristine, and taxol (Gottesman, 2002). The binding of these drugs results in 
activation of one ATP-binding domain. Hydrolysis of ATP results in a conformational 
change in Pgp, which then releases the drug into the extraeellular spaee. Hydrolysis of a 
second ATP molecule is required to restore the protein to its original state (Gottesman, 
2002).
P-glyeoprotein has observed to be overexpressed in many human eaneers, including 
cancers of the gastrointestinal tract, cancers of the hematopoietie system, cancers of the 
genitourinary system, and ehildhood cancers (Goldstein et al., 1989). One of the first 
studies reporting increased Pgp expression in elinical tumour samples involved two women 
with ovarian cancer being treated by ehemotherapeutic agents (Bell et al., 1985). There is 
also considerable evidenee of highly expressed Pgp in renal (Fojo et al., 1987) and eolon 
tumours (Weinstein et al., 1991). In other cases, an inerease in Pgp expression is seen only 
after exposure to ehemotherapeutie drugs or during relapse (Chan et al., 1996). The majority
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of clinical efforts to overcome multidrug resistance related to Pgp expression aim to inhibit 
Pgp’s activity. These clinical trials have had limited success (Gottesman, 2002). Much 
effort has also been put forth to reverse MDR via inhibition of Pgp expression at the DNA 
and RNA level (Lee, 2003). For instance, ecteinascidin 743, an anti-tumour agent, has 
shown promising pre-clinical results in inhibiting Pgp activation (Jin et ah, 2000). Also more 
recently, transcription has been targeted by modulation of the nuclear receptor SXR (Synold, 
Dussault, and Forman, 2001). Strategies have also been suggested involving the use of 
antisense and transcriptional decoy (Marthinet et ah, 2000) and anti-MDRl mRNA 
hammerhead ribozymes (Wang et ah, 1999). In the treatment of human cancers, Pgp 
expression has been associated with chemotherapy failure and decreased survival, therefore 
its regulation is of great clinical importance.
1.0.4 Regulation of Pgp Expression
Regulation of Pgp expression is of great importance in cancer research as its 
overexpression has been implicated as the main reason for the development of multidrug 
resistance. These observations have provoked profound studies related to the regulation of 
Pgp expression. It has been shown that anticancer drugs (Fardel et ah, 1997; Schrenk et ah, 
1996; Zhou and Kuo, 1998; Furuya et ah, 1997), carcinogens (Fardel et ah, 1996; 
Nakatsukasa et ah, 1993), UV irradiation (Zhen, Shengkan, and Scotto, 2000; Uchiumi et ah, 
1993), extracellular matrix proteins (Tatsuta et ah, 1994), heat shock (Chin et ah, 1990), 
transcription factors (Thottassery et ah, 1999; Bargou et al, 1997; Chin et ah, 1992), and 
reactive oxygen species (Ziemann et ah, 1999) participate in overexpression of Pgp in human 
tissues and animal models. Pgp 1 and Pgp2 have been shown to be overexpressed in all 
models of rat and mouse liver carcinogenesis (Lee, Bradley, and Ling, 1998; Kren, Trembley
and Steer, 1996). An increase in Pgp2 gene expression has been observed during liver 
regeneration (Nakatsukasa et al., 1993; Teeter et al., 1993; Marino, Gottesman, and Pastan, 
1989; Thorgeirsson et al., 1987), during establishment of primary hepatoeytes (Lee, Bradley 
and Ling, 1995; Hirsch-Ernst et al., 1995; Schuetz et al., 1995), in tissues treated with 
cyclohexamide (Lee, 2001), and in uteral tissues during pregnancy (Croop et al., 1989; Kuo 
et al., 1995). Interestingly, mRNA stability has been demonstrated in the regeneration of rat 
liver (Kren et al., 1996) and in liver tumours (Lee, Bradley, and Ling, 1998). There has also 
been evidence of post-transcriptional control of Pgp in the uterus (Kuo et al., 1995), intestine 
(Chianale et al., 1995) and in rat tissues subjected to cyclohexamide (Lee, 2001). It has also 
been determined that DNA cross linking agents can suppress MDRl gene expression at two 
independent steps, one at the level of mRNA transcription, and the other at the post 
transcriptional level (Maitra et al., 2001) More recently, it has been suggested that Pgp 
expression is regulated at two specific steps in human leukemic cells. These steps include 
mRNA stabilization and translational initiation (Yague et al., 2003). However, the distinct 
mechanisms of how regulation occurs at these two steps, in either case, has yet to be 
determined. Overexpression of Pgp has also been demonstrated in many rat liver 
carcinogenesis models (Lee et al., 1998; Kuo et al., 1995, Nakatsukasa et al., 1993; Teeter et 
al., 1993; Teeter et al., 1990). In a transplantable rat liver tumour line. Pgp mRNAs 
exhibited an increase in stabilization, in comparison to normal liver Pgp mRNA. This has 
been confirmed through the analysis of mRNA half-lives of the three Pgp. Pgpl, Pgp2 and 
Pgp3 have a half-life of approximately 1-2 hours in normal liver. In liver tumours, all three 
Pgp mRNA demonstrated a half-life of over 12 hours (Table 1.2) (Lee et al., 1998). This
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indicates that Pgp mRNA in liver tumours is more stable in comparison to normal liver, 
which accounts for an increase in Pgp mRNA overexpression in liver tumours.
Table 1.3. P-glycoprotein mRNA half lives (t V2) (h) in liver and transplantable liver tumours (modified 
from Lee et al., 1998)
Genes Liver Transplantable Liver Tumours
Pgpl < 1 > 12
Pgp2 < 1 > 12
Pgp3 1.8 > 12
Mounting evidence suggesting mRNA stability is at least one major mechanism 
resulting in the overexpression of Pgp (Lee et ah, 1998). This warrents further investigation 
into the molecular mechanisms responsible for the increase in stability demonstrated.
1.1 Messenger RNA Stability
The importance of regulating mRNA stability is shown by the extent of physiological 
and clinical events that are affected by change in stability (Dodson and Shapiro, 2002). 
These include development, cell cycle, viral infections, reproduction, and response to cellular 
environment changes (Dodson and Shapiro, 2002). Messenger RNA stability is very 
important in relation to protein expression. The length of time mRNA is intact in the 
cytoplasm directly determines the amount of protein translated (Ross, 1995). Simply, the 
more stable mRNA transcripts are, the more protein is expressed. In retrospect, if the mRNA 
transcript is destabilized, less protein production occurs. The molecular mechanisms for 
activating mRNA degradation or stabilization, particularly in the mammalian system, are not 
well understood. It also appears that the mechanisms involved and the decay processes that 
exist in prokaryotic and eukaryotic systems are not conserved, leading to more complication 
regarding the issue.
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1.1.1 Messenger RNA Stability in Prokaryotes
Prokaryotic mRNA has been observed to be very unstable, and decay rates vary 
extensively (Coburn and Mackie, 1999). There are many factors and pathways involved in 
the degradation and stabililty of prokaryote mRNA, however the exact mechanisms are not 
known, and the main nucleases involved only have loose primary sequenees or secondary 
structure specificity (Grunberg-Manago, 1999). mRNA stability is also reliant on several 
external factors such as growth conditions, environmental signals, and efficiency of 
translation. It is known that decay is always initiated by endoribonucleolytic cleavage by 
RNase E or RNAse III. RNase E has been found to cleave substrates nonspecifically 5’ to 
AU dinucleotides in single stranded segments (Mackie, 1998). RNase III cleaves double 
stranded RNA molecules either with a single strand nick or a double strand break. 
Endonueleolytic cleavage is followed by exonucleolytic decay at the 3’ end. There have 
been two enzymes responsible for exonucleolytie decay including Polynucleotide 
Pbospborylase (PNPase) and RNase II. PNPase catalyzes pbospborolysis of mRNA 
liberating nueleoside diphosphates, while RNase II catalyzes hydrolysis of mRNA releasing 
5’ monophosphates (Grunberg-Manago, 1999). A multienzyme complex, eommonly known 
as the degradosome has also been identified to play a role in the decay process. It appears 
that the degradosome is eomprised of RNase E, PNPase, a glycolytic enzyme, and different 
enzymes using ATP as a cofactor. The functional role of the degradosome is unclear, 
although it is obviously involved in the decay process of bacterial mRNA transcripts 
(Grunberg-Manago, 1999). The final major enzyme facilitating mRNA decay processes in 
bacteria is Poly(A) Polymerase. This enzyme adds adenine residues to the 3’ hydroxyl 
termini of a transcript using ATP as a substrate and releasing pyrophosphate. Unlike in
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eukaryotic systems where poly (A) tails are used as stability factors for mRNA transcripts, 
polyadenylation facilitates exonucleolytic decay by providing a single stranded tail for 
PNPase to attack (Grunberg-Manago, 1999).
1.1.2 Messenger RNA Stability in Lower Eukaryotes (Yeast)
The majority of knowledge obtained to date regarding eukaryotic mRNA stability 
and degradation mechanisms arises from studies in the yeast Saccharomyces cerevisiae. 
There are three modes of mRNA decay described in yeast; (i) deadenylation dependant 
decapping, followed by 5’-3’ decay; (ii) deadenylation independent from decapping followed 
by 3’-5’ decay; and (iii) endonucleolytic cleavage. The major mechanism of mRNA decay is 
thought to involve the removal of the 3’poly (A) tail, followed by the removal of the 5’ eap. 
Deadenylation followed by decapping is the mechanism for deadenylation dependent mRNA 
decay and subjects the mRNA structure to 5’-3’and/or 3’-5’ exonuclease activity (Brewer, 
2002; Dodson and Shapiro, 2002; Tucker and Parker, 2000) (summarized in Figure 1.2.). 
Deadenylation in yeast seems to require the use of two agents with exonuclease activity. The 
first contributor is composed of two proteins Ccr4P/CaflP, and the second deadenylase is the 
Pan2p/Pan3p (PAN) exonuclease. The proposed mechanism for deadenylation in yeast 
involves the PAN subunit that may be responsible for initial trimming of the poly (A) tail, 
and further deadenylation by the Ccr4P/CaflP complex. This is followed by removal of the 
7-methyl guanosine cap. The removal of the 5’ cap in yeast involves the decapping enzyme 
Dcplp, and many other protein factors. Decapping is the key step in yeast mRNA 
degradation as it precedes and permits the decay of the mRNA transcript body by exposing it 
to a 5’-3’ exonuclease (Tucker and Parker, 2000).
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Additionally, yeast transcripts can also be degraded in a 3’-5’ direction following 
deadenylation. This is catalyzed by a complex of 3’-5’ exonucleases termed the exosome. It 
is apparent that this degradation pathway is slower than 5’-3’ decay, however it is still crucial 
to development as mutations that inhibit both 5’-3’ decay and 3’-5’ decay are lethal. This 
suggests that both 5’-3’ and 3’-5’ deadenylation dependant degradation are the two 
significant pathways for mRNA turnover in yeast (Tucker & Parker, 2000).
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Figure 1.2. Deadenylation dependant mRNA decay mechanism in yeast (modified from Wilusz et al., 
2001)
Endonucleolytic cleavage has also been identified to play a role in the stabilization 
and destabilization in yeast mRNA transcripts (Brewer, 2002; Dodson and Shapiro, 2002). 
This pathway is reliant on an endoribonuclease to cut the mRNA body internally. This event 
is followed by exonuclease activity. Endoribonuclease pathway in yeast involves an unfolded 
protein in the endoplasmic reticulum. The unfolded protein Irel has both protein kinase and
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endoribonucleic domains. It has been shown to excise introns and degrade RNA in yeast 
during periods of cell stress (Tirasophon et ah, 2000).
Another method of mRNA decay in lower eukaryotes is termed nonsense-mediated 
decay or RNA surveillance. This process targets mRNA transcripts containing error, and is 
therefore involved in the regulation of mRNA. Error can include: nonsense mutations or 
early termination codons and improperly spliced introns. This pathway has been studied 
extensively in yeast, and occurs through decapping independent of deadenylation (Dodson 
and Shapiro, 2002), followed by 5’-3’ degradation in the cytoplasm (Brewer, 2002). The 
same deeapping enzyme used in deadenylation dependant decay, is also used for nonsense- 
mediated decay. Four additional factors have been identified and deemed crucial for 
nonsense-mediated decay in yeast. These included U pfl, Upf2, Upf3, and Hrpl. It is 
hypothesized that these factors interact to form a ‘surveillance’ complex, and associate with 
release factors at translation termination. The complex then scans the downstream portion of 
the transcript for a premature termination signal. Hrpl interacts with the premature 
termination signal and is thought to act as a marker for targeted nonsense mediated decay 
(Wilusz et al., 2001).
1.3 Messenger RNA decay in Higher Eukaryotes
1.3.1 Mode of mRNA decay
The mode of messenger RNA decay in vertebrates is currently an unresolved issue. 
To date, deadenylation dependant decay has been shown to be an important mode of mRNA 
decay in mammalian cells. The postulated mechanism for this process involves the enzyme 
poly (A) ribonuclease (PARN), first purified from the thymus of a calf (Brewer, 2002). The
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binding of PARN to the 7-methyl guanosine cap activates the processing of the poly(A) tail 
and suggests a link between decapping and deadenylation. A decapping enzyme has also 
been identified in mammalian systems. DcpS is an enzyme thought to decap an mRNA 
transcript that has previously undergone deadenylation and extensive 3’-5’ exonuclease 
degradation (Brewer, 2002). The exact deadenylation-dependant mRNA decay method has 
not been fully characterized in vertebrates and research into the exact mechanism is still 
ongoing (Dodson and Shapiro, 2002).
Unlike in lower eukaryotes, there has been no evidence thus far suggesting that 5’-3’ 
exonuclease decay participates in mRNA regulation in vertebrates. There has been however, 
substantial evidence indicating that endonucleolytic activity also plays an active role in the 
decay process of vertebrate mRNA (summarized in Figure 1.3.). mRNA control can be 
obtained by regulation of endoribonuclease activity, controlling the accessibility of the 
cleavage site, or regulating both levels of control (Dodson and Shapiro, 2002). 
Endoribonucleic activity seems to be triggered in response to cellular crisis or infection that 
is characterized by the presence of double stranded RNA (dsRNA). There are two pathways 
identified in higher eukaryotes which demonstrate that an endoribonuclease can be activated 
in response to dsRNA. The first involves the synthesis of a 2 ’-5’ linked oligoadenylate (2- 
5A) in response to viral infection. This in turn activates RNAse L that cleaves the RNA 
strand at UU or UA residues (Starck et ah, 1998). The second mechanism involves 
interference RNA that targets specific endoribonucleaic cleavage in response to dsRNA. The 
activated endoribonuclease cleaves the dsRNA into 21-23 nucleotide fragments (Sharp,
2001).
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Figure 1.3. General mechanism of endoribonucleic decay in vertebrates (modified from Wilusz et a!.,
2001)
Cleavage site regulation is also important in controlling mRNA degradation. As later 
described in detail, mRNA contains cA-elements (section 3.0.2.). These elements can act as 
cleavage sites for specific endoribonuclease activity. Cleavage by an endoribonuclease 
produces RNA fragments with unprotected 5’ and 3’ ends. This in turn makes the products 
very susceptible to exonuclease activity. Protection of the cleavage sites can occur through 
RNA-binding proteins. For example, control of c-myc mRNA has been shown to be partially 
dependent on an approximately 75 kDa protein that is normally bound to the c-myc coding 
region determinant (Bernstein et al., 1992). This protein acts to protect the mRNA from a 39 
kDa endoribonuclease that cleaves the coding region stability determinant in a very specific 
manner (Lee et al., 1998). This has also been demonstrated in TfR (transferrin receptor) 
mRNA. It has been shown that the iron response element binding protein (IREBP) increases 
in response to low levels of iron. The binding of this protein to iron response elements in the 
3’ UTR of transferrin receptor mRNA protects it from endoribonucleic attack (Dodson and 
Shaprio, 2002).
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In some cases, it has been demonstrated that mRNA processing involves both 
endoribonucleic degradation and deadenylation-dependant degradation, c-myc and a-globin 
are examples where both mechanisms are used to regulate mRNA. Both mRNAs contain cis 
elements that bind to proteins that protect the mRNA strand from endoribonucleic cleavage. 
Both are also destabilized by deadenylation-dependant mechanisms (Dodson and Shapiro,
2002).
Finally, endoribonucleolytic decay mechanisms for mRNA have been identified in 
Xenopus, chickens, yeast, and mammals. The endonucleases themselves are different in not 
only the sequences they target, but the structure as well. Endoribonucleases have been 
identified that cleave A rich segments (Tfr and c-myc), U rich segments (p27kipl), C rich 
segments (a-globin), G rich segments (Igf II and PGK), AU rich segments (apolipoprotein II 
and gro-a), and ACU rich segments (Hep B, Xlhbox2B, and 9E3) (Dodson & Shapiro, 2002). 
Most endoribonuclease cleavage sites identified are single stranded, although some have 
shown to be dependant on secondary RNA structure (IGF II and apolipoprotein). There have 
been very few mRNA decay intermediates identified in-vivo due to the instability of 
degradation products. To date very few endoribonucleases have been purified and cloned 
(summarized in Table 1.4.). The ones that have been characterized range in size from 13 to 
120 kDa, and are found in a variety of locations such as the cytosol, nucleus, and polysomes 
(Dodson and Shapiro, 2002).
Nonsense mediated decay has also been identified in higher eukaryotes as a 
mechanism for mRNA regulation. The exact mechanism is still unclear, although this 
process appears to be associated with first round translation (Dodson and Shapiro, 2002) and 
requires specific nuclear events that differ from nonsense mediated decay in yeast (Brewer,
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2002). For example, nonsense mediated decay in mammalian cells requires essential 
components not encoded in the yeast genome (Brewer, 2002). In mammalian cells a 
premature termination codon is identified if it is located at least 50 -  55 nucleotides from the 
exon-exon junction at the 3’ UTR. It is thought that this junction could lead to the 
association of Upf3, Upf2, and Upfl. It is not clear if these factors associate sequentially, or 
how they target mRNA for nonsense mediated decay in vertebrates (Brewer, 2002; Dodson 
and Shapiro, 2002).
1.3.2 CM-Elements in mRNA Decay/Stability
Various mechanisms related to the regulation of unstable mRNA transcripts in 
vertebrates are also known. Unstable mRNA transcripts such as those belonging to 
cytokines, growth factors, and transcription factors are regulated by the presence of cis 
destabilizing elements that bind to tran^-acting factors. This is thought to accelerate or slow 
entry into the deadenylation dependant decay pathway (Gao et al., 2001; Shyu et al., 1989). 
There are two elements identified which play this role. The first is the AU-rich element, 
which is found in a number of mRNAs, the second is Major Coding Region Determinants 
found in c-fos mRNA.
AU-rich elements (AREs) are cis elements (Dodson and Shapiro, 2002), and have 
been grouped into three main classes associated with the mammalian system. Class I AREs 
represent one or more AUUUA pentamers within a U rich region; class II AREs contain 
tandem repeats of the AUUUA sequence; and class III are U-rich and are not associated with 
the AUUUA motif (Brewer, 2002). mRNA transcripts containing class I and III AREs have 
been shown to encode oncogenes. mRNAs containing class II AREs often encode cytokines 
and chemokines (Brewer, 2002). All AREs are located in the 3’ UTR (Brewer, 2002).
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Depending on the cellular environment, different AREs can have different effects on mRNA 
transcripts (Chen and Shyu, 1995; Peng et ah, 1998). There are also many ARE binding 
proteins that have been identified (Wilusz et ah, 2001) which are regulated by various factors 
such as stress activated kinases, membrane receptors, and members of the steroid receptor 
family (Sela-Brown et al., 2000; Sheflin et al., 2001). Levels of AREs are also variable 
during physiological processes such as development, cell senescence, and stress (Wang et al., 
2001). The variability surrounding AREs and their ability to be stabilizing or destabilizing 
agents, seems to be related to the interaction with trans-acting factors (Dodson and Shapiro, 
2002X
1.3.3 Specific Examples of mRNA Stability/Decay
Two mammalian mRNA transcripts have been identified to require specific 
mechanisms related to stability and decay processes. Mammalian c-fos mRNA is one 
example, c-fos mRNA has an ARE present in the 3’ UTR. In addition to the ARE, it also 
has a second element called mCRDl (major coding region instability element) that is 
involved in degradation regulation. The mCRDl is a purine-rieh segment upstream from the 
poly (A) tail. The distance between the poly (A) tail and the mCRDl segment is important as 
there are five proteins that bind to this region. These proteins include UNr (a purine-rich 
RNA-binding protein), poly (A)-binding interacting protein, PABP (poly (A) binding 
protein), NSAIPI, and AUFl (Grosset et al., 2000). The interaction between these proteins, 
the coding region determinant and deadenylation mechanisms appear to control the stability 
of c-fos mRNA in a seemingly complicated mechanism (Dodson and Shapiro, 2002).
Mammalian c-myc mRNA is another example of an mRNA transcript whose stability 
and decay is very specific in nature. Two stability determinants have been identified in c-myc
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mRNA. One is present in 3’UTR, and the other is located within the coding region 
(Bernstein, et al. 1992). The coding region stability determinant has also shown to have 
instability determinant properties, and act as a site for endonucleolytic cleavage. As 
previously stated, it has been demonstrated tbat c-myc mRNA can be degraded via two 
separate mechanisms. One mechanism involves an exonuclease that contributes to the 
deadenylation dependant 3’-5’ degradation process. The second mechanism involves an 
endoribonuclease that cleaves the coding region stability determinant in predominantly A- 
rich segments (Lee et al., 1998). As also previously described, the ability of the 
endoribonuclease to cleave c-myc mRNA is dependant on the presence of a coding redion 
determinant binding protein. The combination of degradation mechanisms and 
stability/instability determinants present in c-myc RNA make it an interesting example of 
how complicated the study of mammalian mRNA stability and decay can be.
1.4 Objectives
One method for studying mRNA decay involves the analysis of mRNA degradation 
intermediates. Degradation intermediates have been identified for several mammalian 
mRNAs, including c-myc (loannidis et al., 1996) and albumin mRNA in mouse liver (Tharun 
and Sirdeshmukh, 1995). It is thought that in some instances the presence of degradation 
products is a regulated event (Tharun and Sideshmukh, 1995), and in some cases has lead to 
the purification and characterization of an endoribonuclease (Lee et al., 1998). Another 
method for studying mRNA decay mechanisms involves the use of polysomes or extracts in 
in vitro reactions. This method allows better detection of mRNA degradation products as
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well as the enzymes and other molecules involved in the degradation process (Brewer and 
Ross, 1990).
In an effort to understand the mechanism for overexpression of Pgp2 mRNA in rat 
liver tumours, measurements of the half life of Pgp2 mRNA in both normal liver and liver 
tumour were determined. As indicated above (Table 1.2) it was determined that the half life 
for Pgp2 mRNA in normal liver was less than 1.8 hours, while the half life of Pgp2 mRNA in 
liver tumours extended to over twelve hours (Lee, Bradley, and Ling, 1998). The mechanism 
responsible for the increased mRNA stability demonstrated in rat liver tumours is unknown. 
This study aims at comparing the in vivo degradation pathway of Pgp2 mRNA in normal 
liver and liver tumour in rats, in an effort to determine what causes Pgp2 mRNA to be more 
stable in liver tumour. One approach to determine the in vivo degradation pathway of Pgp2 
mRNA is through identification of Pgp2 mRNA degradation intermediates in liver tumour 
and normal liver. If similar Pgp2 mRNA degradation products are found in both normal liver 
and liver tumours, this would suggest similar degradation pathways. This would still be an 
interesting finding because little is known about Pgp2 mRNA decay pathway. Furthermore, 
this will provide some insight into the general decay process of mRNA in an animal system. 
Presence of Pgp2 mRNA decay produet(s) in one tissue and not the other, would suggest 
differential decay pathways. Results obtained from this portion of the study could potentially 
explain the underlying mechanisms for increased Pgp2 mRNA stability in liver tumours. 
Advances in the knowledge of how Pgp mRNA is stabilized and degraded can lead to 
development of therapeutic strategies against Pgp over expression observed in many cancers.
The focus of this research is to detect and analyze rat Pgp2 mRNA degradation 
products in normal liver and liver tumour, in an effort to compare the in vivo degradation
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pathway of Pgp2 mRNA in both tissue samples. The major objectives of this study have 
been divided into three chapters. Chapter 2 describes the establishment and optimization of 
the Yeast Poly (A) RT-PCR protocol to detect possible degradation intermediates. Chapter 3 
describes the use of the Yeast Poly (A) RT-PCR method to detect possible Pgp2 mRNA 
degradation intermediates in total RNA isolated from liver tumour and normal liver. Chapter 
4 describes the use of Primer Extension analysis to determine the nature of cleavage of 
detected degradation product(s). A general discussion related to the ability of this study to 
meet the set objectives, and possible directions for future research related to Pgp2 mRNA 
stability is provided in Chapter 5.
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Table 1.4. A comprehensive list of endonucleases identifîed and their properties (modified from Dodson & Shapiro, 2002).
mRNA Cleavage Site Name Size
(kDa)
Location Activator Binding
Protein
Reference
Undefined' c-myc 3’-UTR G3BP 120 Cytoplasm P 04 Not
identified
Gallonzi et ah, 
1998
Albumin^ APryUGA, 
3’-UTR
PMR-1 60 Polysomes Estrogen Not
identified
Cunningham et 
ah ,2001
A-Globin CCCUCCUUGGACC 
> 24 nt. 3’-UTR
ErEN Not
known
Non-
polysomal
Erythroid-
enriched
aCP Wang et ah, 2000
Undefined' AU-rich, ssRNA 
RNAse E substrates
ARDl 13.3 Polysomes Not
identifed
Not
identifed
Wennborg et ah, 
1995; Claverie- 
Martin et ah, 
1997
p27kipl UUCGGUUUGUUUU 
UU, 5 ’-UTR
Endonuclease 
in HUR 
binding site
Not
known
Not known Not
identified
HUR Zhao et ah, 2000
Viral RNA AA and AU ssRNA RNase L 40 ,80 ER INF, 2-5A Not
identifed
Gallonzi et al., 
1998
Irel CUGCAG,
AAAACUA,
AGUGAA
IREl 110 ER Unfolded
Protein
Not
identifed
Tirasophon et al., 
2000
’ endogenous substrate unknown 
 ^isolated from Xenopus laevis
Chapter 2 
Establishing and Optimizing the Yeast Poly(A) Tailing RT-PCR Method to Detect RNA 
Molecules In-vitro
This chapter describes the establishment and optimization of the Yeast Poly (A) 
tailing RT-PCR protocol used for detection of putative Pgp2 mRNA degradation 
intermediates. The sensitivity of the Yeast Poly (A) tailing RT-PCR assay is determined by 
running Poly(A)-tailed RT-PCR products of in-vitro transcribed RNA, on 6% denaturing 
polyacrylamide/7M urea gel and on 1.5% agarose gel. Methodology, results and discussion 
related to these topics are ineluded.
2.0 Methods
2.0.1 In-vitro transcription of pGEM4Z-Pgp2 Plasmids
Plasmid constructs designated pGEM4Z-Pgp2A, pGEM4Z-Pgp2B 1, pGEM4Z-Pgp2C, 
PGEM4Z-Pgp2D, and pGEM4Z-Pgp2El contain different segments of Pgp2 eDNA were 
used (Silverman et al., 1991; Fig.2.1.). All plasmids were linearized with the restriction 
enzyme Hindlll to prepare for in-vitro transcription (see Figure 2.2. for detail of pGEM4Z 
plasmid). Plasmid DNA (15 pg) was added to 10 pL of Hindlll, 3 pL of lOX Reaction 
buffer, and double distilled water (ddHiO) to make the reaetion mixture up to 30 pL. The 
mixture was ineubated at 37° C for 3 hours. 2 pL of linearized plasmid was then loaded and 
run on an ethidium bromide stained 1% agarose gel. The gel was visualized and a 
photograph was taken using Chemilmager'i'’^  System (Alpha Innoteeh Corporation, San 
Leandro, CA).
Onee linearized 170 pL of ddH20 was added to make the volume up to 200 pL. The 
standard phenol ehloroform extraetion was performed as follows: 100 pL of phenol and 100
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[iL of chloroform;isoamylalcohol (CHClsiIAA) (49:1) were added to the linearized plasmid 
solution. The solution was vortexed and then centrifuged at 12,000 rpm for 5 minutes. The 
aqueous layer was transferred to a new microcentrifuge tube and one volume of CHCl^iIAA 
was added to the new tube. The solution was vortexed and centrifuged for an additional five 
minutes to remove any excess phenol. The top layer was
A lG W IO j) llGA(nt3933) 
ZZZZZHZzlz^ l^ 3'
1057-IS55 nt 
pGEVWZfgpZD
4254 nis
I&52 2656 nt
12652 3454 nt
13452^229 nt 
pGE\MZrPg^A
Figure 2.1. Pgp2 cDNA constructs used for making in-vitro RNA controls in Yeast PoIy(A) 
tailing RT-PCR method. (Constructs were designed based on cloning of Pgp2 mRNA accomplished by 
Silverman et al., 1991)
SMI WO II 226 2
Vector
1 S ian
ECOFO 7
S K l 17
K p o l 23
Awal 2 3
XirrM 1 23
$TTMl 25
B am H  1 23
XUBi 3 4
a ' l 40
Â cc  1 41
H f ic  11 42
SO
S W 'l 56
M n d  III 58
T  T t
70
Figure 2.2. pGEM4Z cloning vector used for the construction of 
Pgp2 cDNA constructs (Promega, Madison, WI).
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again transferred to a new tube and the Standard Ethanol Precipitation was performed as 
follows: two volumes of 100% ethanol and I/IO'*’ of the volume of 3 M sodium acetate 
(NaOAe) pH 5.2 were added and the solution was mixed thoroughly. The mixture was then 
stored at -20° C for 20 minutes to precipitate the plasmid DNA. The solution was removed 
and centrifuged for ten minutes at 12,000 rpm. The supernatant was removed and the DNA 
pellet was washed by gently adding 200 pL of 70% cold ethanol. The sample was then 
centrifuged for five minutes and the supernatant was aspirated. The DNA pellet was then 
allowed to air dry for 15 minutes and was resuspended in 10 pL of ddHaO.
RNA was synthesized using MEGAscript® SP6 Kit (Ambion, Inc., Austin, Texas). 
The in- vitro transcribed RNA will be used as a control for verification of the Yeast Poly (A) 
tailing RT-PCR method. Each in-vitro transcription reaetion entailed: 4 pL of linearized 
plasmid DNA; 2 uL of 10 X reaction buffer; 2 pL of each 50 mM ATP, CTP, UTP, and OTP; 
2 pL of SP6 RNA polymerase; and 4 pL of diethylpyroearbonate (DEPC) H2 O. The mixture 
was ineubated at 37° C for 2 hours followed by an addition of 1 pL of DNase I. The reaetion 
was ineubated again at 37° C for 15 minutes. DEPC H 2 O was then added to make the 
reaction mixture up to 200 pL and the Standard Phenol/Chloroform Extraetion, Standard 
Ethanol Precipitation was performed. The pellet was resuspended in 50 pL of DEPC H2O, 
and the solution was added to a ProbeQuant^^ G-50 Micro Column (Amersham Pharmacia 
Biotech). The column was centrifuged for 2 minutes at 3,000 rpm and the RNA sample was 
collected in a new microcentrifuge tube. The quality of RNA was checked by running 3 pL 
of column sample with 3 pL cocktail mix [10 X MOPS (N-morpholino propanesulfonic acid, 
EDTA, NaOAe, ddH20, DEPC H2 O), formaldehyde, formamide, ethidium bromide, and
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DEPC H2O and 2[iL loading dye on a 1.3% formaldehyde gel. The gel was visualized and 
photographed using Chemilmager^M System.
2.0.2 Poly(A)-Tailing, Reverse Transcription of In-vitro transcribed Pgp 2E1
RNA
In-vitro transcribed Pgp2El RNA was determined to be of good quality RNA sample 
(Figure 2.4., lane 5) and therefore was used to test the sensitivity of this assay. Pgp2E 1 RNA 
(100 ng) was incubated at 65°C for 5 minutes, and then placed on ice. To the sample the 
following reagents were added: 2 gL of 5X reaction buffer; 1 p,L of 10 mM ATP; 0.5 gL 
RNasin (40 U/gL) (Promega, Madison, WI ); 0.5 qL 100 mM DL-Dithiothreitol (DTT); 1 gL 
Yeast Poly(A) Polymerase (600 U/gL) (USB Corp., Cleveland, OH); and 4 gL DEPC HoO. 
The solution was incubated at 30°C for 10 minutes and then incubated at 65 °C for an 
additional 10 minutes. The sample then underwent a reverse transcription reaction where the 
10 [xL of Pgp2El tailed-RNA was again incubated at 65°C for five minutes and then placed 
on ice. The following reagents were then added: 2 gL of lOmM deoxyribonucleoside 
triphosphates (dNTPs); 4 pL of 5X AMV Buffer; 1 pL of OligodTig-Xhol primer
100 mM DTT; 1 pL RNasin (20 U/pL); and 1 pL of AMV reverse transcriptase (5U/pL) 
(Roche Applied Science, Basel, Switzerland). The solution was incubated at 37°C for 20 
minutes, followed by incubation at 50°C for 15 minutes. The enzymes were heat activated 
by incubation at 65°C for 10 minutes. As a control to test if Poly (A) tailing of Pgp2El in- 
vitro transcribed RNA was successful, reverse transcription was carried out on non-tailed 
RNA samples as well.
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2.0.3 Déphosphorylation and Phosphorylation of Forward Primers
It was necessary to 5’ label forward primers with y^^P-ATP (50pCi) (Amersham 
Biosciences Corp, Piscataway, NJ) prior to use for PCR of tailed and nontailed RT samples 
for analysis on 6% polyacrylamide/7 M urea gel. The primers first needed to be 
dephoshorylated. Each dephosphorylation reaction included: 10 [rg of forward primer, 10 
pL of Calf Intestinal Alkaline Phophatase (CIAP) (1 U/pL) (Roche Applied Science, Basel, 
Switzerland); 10 pL of 10 X dephosphorylation buffer; and ddHaO to make the final reaction 
volume up to 100 pL. The reaction mixture was incubated at 37 °C for 30 minutes and 100 
pL of ddHiO was added. The standard phenol/chloroform extraetion and the standard 
ethanol precipitation were performed and the DNA pellet was resuspended in 20 pL of 
ddHzO.
The phosphorylation reaction of dephosphorylated primers included the following 
reagents: 10 pL of dephosphorylated primer; 5pL of 5 X phosphorylation buffer; 5 pL of 
y32p_ATP; 3  (10 U/pL) of T4 Polynucleotide kinase (New England Biolabs, Beverly,
MA); and ddHaO to make the final reaction volume to 25 pL. The reaction mixture was 
incubated at 37°C for one hour and ddH20 was added to make the volume up to 50 pL. The 
sample was added to a ProbeQuant^'^ G-50 Micro Column and centrifuged for 2 minutes at
3,000 rpm. The sample was collected in a new microcentrifuge tube and ddHaO was added 
to make the final volume to 200 pL. The standard phenol/chloroform extraction was 
performed, followed by the standard ethanol -precipitation. The DNA pellet was 
resuspended in 200 pL of ddHiO. IpL  of sample was used for scintillation counting.
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2.0.4 Amplification of Poly (A) Tailed Pgp2El cDNA through Polymerase 
Chain Reaction
In order to test the sensitivity of this technique on both a 6% polyacrylamide/7 M 
urea gel and a 1.5 % agaorse gel, two different PCR reactions were set up. The reaction 
intended for polyacrylamide gel analysis included: 2 pL of tailed-RT Pgp2El cDNA 
template ranging in concentration from 0 ng/pL to 400ng/pL; 3.5 pL of lOX PCR Buffer 
(New England Biolabs); 3.5 pL of 2.5 mM dNTPs; 1 pL 50 mM MgCl]; 5 pL (100 ng/pL) of 
y^^P-ATP 5’ labeled EFl forward primer; 1 pL of reverse OligodTig-XhoI (100 ng/pL); 1 pL 
(5 U/pL) of Taq Polymerase (Invitrogen Life Technologies, Carlsbad, CA); and ddH^O to 
make the final reaction volume up to 35 pL. The reaction intended for anlaysis on a 1.5% 
ethidium bromide stained agaorse gel involved the substitution of the labeled EE 1 forward 
primer for unlabeled EEl forward primer (100 ng/pL). PCR parameters were set at 94°C for 
30 sec; 50°C for 30 sec; and 72°C for 45 seconds for 30 cycles on a Minicycler™ Peltier 
Thermal Cycler (MJ Research, Inc., Reno, NV). Unlabeled products were ran on a 1.5% 
ethidium bromide stained agarose gel with 0.5 X TBE buffer and were visualized using 
Chemilmager'i''^ System.
Labeled products of the first PCR experiment were run for 3 hours on a 6% 
polyacrylamide/7M urea gel with I X TBE (tris base, boric acid, EDTA) buffer. The gel 
was dried and exposed for 24 hours. The image was scanned using Cyclone phosphorimager, 
and visualized using the OpiQuant software (Hewlett Packard, Palo Alto, CA).
30
2.1 Results
2.1.1 Digestion of pGEM4Z-Pgp2 Plasmids
pGEM4Z-Pgp2 plasmids are double stranded eircular DNA moleeules derived from 
bacteria. The circular structure of the intact plasmid molecule appears as two bands after gel 
electrophoresis. The major band (approximately 1800 bp) is the plasmid DNA, whereas the 
top band represents nicked plasmid DNA. All plasmids underwent a restriction digest with 
Hindlll (Figure 2.3.) to prepare for in-vitro transcription. One band is detected in all 
digested plasmid samples except for pGEM4Z-Pgp2B 1 (lane 5). pGEM4Z-Pgp2B 1 plasmid 
exhibits two faint bands due to incomplete digestion.
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Figure 2.3. pGEM4Z Pgp2 plasmids linearized with restriction enzyme with Hind III in 
preparation for in-vitro transcription on 1 % agarose gel. Even numbered lanes exhibit intact 
pGEM4Z Pgp2 plasminds. Odd numbered lanes show plasmid samples that underwent 
restriction digest with Hind HI.
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2.1.2 In-vitro transcription of digested pGEM4Z-Pgp2 plasmids
A digest (1-3 |iL) sample of each in-vitro transcribed Pgp2 RNA was ran on a 1.3 % 
formaldehyde gel to visualize the RNA (Figure 2.4.). A major species of in-vitro transcribed 
RNA was detected for all samples corresponding to the approximate expected length 
(see Figure 2.2.; most intense band in Figure 2.4.) except for Pgp2A (lane 1). In-vitro 
transcription of Pgp2A plasmid has resulted in 3 distinct bands. This has been observed in the 
hands of other experimenters in the lab. In-vitro transcribed Pgp2C, and Pgp2D also exhibit 
a secondary RNA species (lanes 3 and 4). In-vitro transcribed Pgp2Bl (lane 2) and Pgp2El 
(lane 5) both exhibit only one species of RNA (lanes 2 and 5). Pgp2El RNA was chosen for 
further studies as it exhibited one intense distinct major species.(see Methods 2.0.2 and
2.0.4).
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on a 1.3% formaldehyde gel. 
Linearized plasmid samples were 
subjected to in-vitro transcription 
using MEGAscript® SP 6 K it 
(Ambion)
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2,1,3 Visualization of unlabeled Poly(A) tailed RT-PCR products on a 1,5%
agaorse gel
Concentrations of poly(A) tailed in-vitro transcribed Pgp2El RNA products from 0 
ng/pL to 400 ng/pL were amplified by PCR and were ran on a 1.5% ethidium bromide 
stained agarose gel to determine the sensitivity of this method (Figure 2.5.). Detection of 
Poly(A) tailed Pgp2El in-vitro transcribed RNA (most intense band with a size approximate 
to 1018 bp) was possible from 400 ng/pL to 0.4 ng/pL (lanes 7 to 11). A less distinct band 
was present at approximately 506 bp and was detected from 400 ng/pL to 1 ng/pL. Two 
bands shown at the bottom of the gel in Figure 2.4. are primers.
I 1o 1s 1 1 1 1 1 1 Î: : oo oo Tfd c cTf ? I
1018-
506-
396-
Pgp2El RNA
Primers
Figure 2.5, Concentrations of in-vitro transcribed Pgp2El RNA from on a 1.5% agarose 
gel. Concentrations of poly (A) tailed in-vitro transcribed Pgp2El RNA products from 
400 ng/pL to 0 ng/pL were amplified by PCR and visualized to determine tbe sensitivity 
of tbe Yeast Poly (A) Tailing RT-PCR method.
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2.1.4 Visualization of y^^P-ATP labeled Poly(A) tailed RT-PCR products on a
6% denaturing polyacrylamide/urea gel.
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Figure 2.6. Concentrations of in-vitro transcribed Pgp2El RNA on a 6% 
denaturing poiyacrylamide/7M urea gel. Concentrations of poly (A) tailed 
in-vitro transcribed Pgp2El RNA products from 400 ng/pL to 0 ng/pL were 
amplifîed by PCR and visualized to determine the sensitivity of the Yeast 
Poly (A) Tailing RT-PCR method. The marker used is plasmid pBR322 cut 
with restriction enzyme Haelll.
To determine whether the Yeast Poly(A) tailing RT-PCR method would be more 
sensitive, experiments were also carried out using 5’ y^^P-ATP labeled Pgp2El forward 
primer. Concentrations of poly(A) tailed in-vitro transcribed Pgp2El RNA products from
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400 ng/fxL to 0 ng/gL were amplified by PCR and were run on a 6 % denaturing 
poIyacrylamide/7M urea gel to determine the sensitivity of this method (Figure 2.6.). 
Detection of Poly (A) tailed Pgp2El in-vitro transcribed RNA (most intense band with a size 
approximate to 1048 bp) was possible from 400 ng/^iL to 0.001 ng/fxL (lanes 3-10). Several 
less distinct bands were also detected at approximately 600 bp and 400 bp in the same 
samples. Large smears present at the bottom of the gel are primers.
2.2 Discussion
All pGEM4Z-Pgp2 plasmids were successfully linearized after the restriction digest 
with Hind III except for pGEM-Pgp2B 1, as only one distinct band was exhibited when a 
small amount of sample was run on a 1% agarose gel (Figure 2.3.). pGEM-Pgp2B 1 
exhibited partial digestion as one faint band was apparent. In other experiments, complete 
linearization of pGEM-Pgp2B 1 has been observed. This sample was still used for in-vitro 
transcription as some linearized plasmid sample is present.
In-vitro transcription was performed on all pGEM4Z-Pgp2 plasmids. Small samples 
of the newly synthesized RNA were loaded and run on a 1.3% formaldehyde gel to confirm 
successful transcription (Figure 2.4.). Ideally in-vitro transcribed RNA should only exhibit 
one band as seen in Pgp2El and Pgp2Bl RNA (Figure 2.4.). In-vitro transcribed Pgp2C, and 
Pgp2D RNA display two bands. In-vitro transcribed Pgp2A RNA exhibits 3 bands. It is not 
clear why in-vitro transcribed RNA from these plasmids exhibits more than one species. One 
reason could be related to the presence of a premature termination sequence. If a premature 
termination sequence is present in the sequence being transcribed, which is recognizable by 
SP6 RNA polymerase, early termination of transcription would occur. This would explain 
why two or three different samples of in-vitro transcribed RNA are present. However, there
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is no premature stop signal present in any of the plasmid sequences. Therefore, it is possible 
that the structure of the plasmid at certain points may promote dropping off of the SP6 RNA 
polymerase, yielding the possibility of an incomplete transcript being present. A more likely 
explanation involves transcription of incomplete digested plasmid which was not observable 
on an agarose gel. This would lead to the presence of a larger species of RNA, which is 
evident in this case. In any case, this has not hindered analysis of liver and tumour samples 
for Pgp2 mRNA degradation products, as the in-vitro transcribed RNA is only acting as a 
control to test if the Yeast Poly (A) RT PCR method is valid, and does not participate in the 
actual detection of putative decay products.
The Yeast Poly(A) tailing RT-PCR method was able to amplify concentrations of in- 
vitro transcribed Pgp2El RNA from 400 ng/pL to 0.4 ng/pL using unlabelled Pgp2El 
forward primer (Figure 2.5.). The sensitivity of this method was improved when using 5’ 
y^^P-ATP labeled Pgp2El forward primer and run on a 6% denaturing polyacrylamide/urea 
gel (Figure 2.6.). In this case, in-vitro transcribed Pgp2El mRNA could be detected down to 
0.001 ng/pL. These results indicate that the Yeast Poly (A) tailing RT-PCR method is highly 
sensitive in detecting low concentrations of RNA in-vitro. It is imperative to bear in mind 
that the concentration of putative Pgp2 mRNA degradation products in vivo is not known, 
therefore, it is not possible to determine if this method is suitable for in vivo applications. 
One can speculate however, that there is potential for this method to be successful as 0.4 
ng/pL and 0.001 ng/pL are very low concentrations. Upon visualization of the 1.5% agarose 
gel (Figure 2.5.), it was noticed that a less distinct band was visible with a size of 
approximately 506 bp. Several less distinct bands were also present on the 6% 
polyacrylamide/7M urea gel (Figure 2.6.) with sizes approximately 500 bp and 400 bp. It is
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possible that these bands were amplified and represent regions of in-vitro transcribed Pgp2 
mRNA rich in adenine residues where the Oligo dTis-XhoI primer could nonspecifically 
hybridize. It is possible that such nonspecific nature of the Oligo dTig-XhoI primer could 
pose a problem for in vivo applications (Chapter 3); however it will depend on the 
concentration of tailed Pgp2 mRNA degradation products. If the concentration of 
successfully tailed Pgp2 mRNA degradation products is high enough, they should be 
successfully amplified. Due to the sensitivity of this method, observed here in-vitro it was 
determined that this method will be used to detect putative Pgp2 mRNA degradation 
products in normal liver and liver tumour tissue samples.
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Chapter 3
Using Yeast PoIy(A) Tailing Method to Search for Putative Rat Pgp2 mRNA 
Degradation Products in Normal Liver and Liver Tumours
This chapter describes experiments performed to detect putative Pgp2 mRNA 
degradation intermediates in total RNA from normal liver and liver tumours from three 
different animals using the Yeast Poly (A) tailing RT-PCR method. All experimental 
procedures, results, and a discussion related to the use of Yeast Poly (A) tailing RT-PCR 
method are included. This chapter assesses the efficiency of the Yeast Poly (A) tailing RT- 
PCR method in detecting Pgp2 mRNA degradation intermediates. This could potentially 
have implications for detecting any mRNA degradation intermediates in cells or tissues.
3.0 Methods
3.0.1 Poly(A)-TaiIing, Reverse Transcription of In-vitro transcribed Pgp2A,
Pgp2Bl, Pgp2C, Pgp2D and Pgp2El RNA controls and Total RNA isolated from
Normal Liver and Liver Tumour Tissue Samples
All tissue samples previously collected from animals, were subjected to in vivo 
transcriptional inhibition, and were used in experiments described in this thesis (Lee et al., 
1998). Briefly, tissue samples of liver and tumours were collected from rats, which had 
received an intravenous bolus of 50 pg per 100 g body weight of a-amanitin and an 
intraperitoneal dose of 150 pg per 100 g body weight of aetinomyein D. Aetinomyein D and 
a-amanitin are transcriptional inhibitors, therefore halting the process in which mRNA is 
synthesized from a DNA template. Tissue samples obtained from three different animals at 
time points 0, 1, 3, 6, and 12 hours post-injection with transcriptional inhibitors were 
subjected to total RNA isolation (Lee et al., 1998). Total RNA samples at 0 time point were 
analyzed for the possible presence of Pgp2 mRNA degradation products. Figure 3.1. is a 
diagrammatic scheme of the Yeast Poly(A) tailing RT-PCR method. These samples were
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named Liver 0.1, 0.2, 0.3 and Tumour 0.1, 0.2, 0.3. In-vitro transcribed Pgp2 RNA (100 ng) 
and 10 [xg of total RNA from each tissue sample was used for the Poly(A) Tailing method 
(see Methods 2.0.2). All samples then underwent a reverse transcription reaction (see 
Methods 2.0.2) As a control to test if Poly(A) tailing was successful, reverse transcription 
was carried out on non-tailed in-vitro transcribed RNA samples. To test for the presence of 
possible degradation products, reverse transcription was also carried out on nontailed total 
RNA isolated from all six tissue samples.
degraded
RNA
Poly (A) 
AAAAAAAAAAAA Tail
AAAAAAAAAAA
OligodTlS-XhoI 
reverse transcribe  ^ primer
*
PCR with labeled 
mRNA-specific 
primer
Figure 3.1. Summary of the Yeast Poly(A) tail RT-PCR method used to search for putative Pgp2 mRNA 
degradation intermediates.
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3.0.2 Amplifîcation and Purification of Putative Pgp2 mRNA Degradation 
Products
PCR was used to amplify possible degradation products of Pgp2 mRNA in normal 
liver and liver tumour. It was initially thought that identification of possible degradation 
products would only be possible through analysis of 5’ labeled y^^P-ATP PCR products on a 
6% polyacrylamide/7M urea gel. However, due to the apparent sensitivity of the technique 
(see Discussion 2.2), some analysis on cold PCR products were carried out on a 1.5% 
ethidium bromide stained agarose gel. Five general PCR reactions were set up to analyze the 
five segments of Pgp2 mRNA represented by pGEM4Z plasmid constructs (Figure 3.2.). 
Each general reaction included tailed and nontailed samples of the in-vitro transcribed RNA 
sample corresponding to the region of study (i.e. Pgp2El), normal liver (0.1, 0.2, 0.3), and 
liver tumour (0.1, 0.2, 0.3). To each individual reaction the following was added: 3.5 [xL of 
lOX PCR Buffer; 3.5 fxL of 2.5 mM dNTPs; 1 piL 50 mM MgCli; 1 tiL of reverse Oligo 
dTig-XhoI primer (100 ng/pL); 1 pL of Taq Polymerase (5 U/pL); and ddH20 to make the 
final reaction volume up to 35 pL. For PCR reactions involving Pgp2A, Pgp2B 1, and 
Pgp2El as the region of study, 5 pL of y^^P-ATP 5’ labeled 2A, 2B1 and 2E1 forward primer 
respectively, were added to each individual reaction. For PCR reactions involving Pgp2C 
and Pgp2D as the region of study, 5 pL (lOOng/pL) of unlabeled 2C and 2D Forward 
Primers respectively were added to each individual reaction (see Table 3.1 for primer 
sequences). PCR parameters entailed: 94°C for 30 seconds; 50°C for 30 seconds; and 72°C 
for 45 seconds for 30 cycles on a
Minicyeler™ Peltier Thermal Cycler. The PCR products utilizing the labeled primers (2A, 
2B1, and 2E1) were loaded and ran for 3 hours on a 6% polyacrylamide/7M urea gel with 1 
X TBE buffer. The gel was dried and exposed for 24 hours. Autoradiography was carried
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out using Cyclone phosphorimager using the OpiQuant software. PCR products utilizing 
unlabeled forward primers (2D and 2C) were ran on a 1.5% ethidium bromide stained 
agarose gel with 0.5 X TBE buffer and were visualized using C h e m i l m a g e r ^ M  System.
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Figure 3.2. Location of forward primers used in the polymerase chain reaction to amplify possible Pgp2 
mRNA degradation products.
Primer Sequence (5’ -  3’) *
2A forward prim er CTC G G A TC C A G G A G C C C A TC C TG TTTG A C
2 B 1 forward primer CTC G G A TC C C TTA G TC TA TG G C TG G C A G C
2C forward primer CTC G G A TC C A TA G C TC A C C G C TTG TC TA C
2D forward prim er C TC G G A TC C C C TC C TTG G TC C TC TA A A T
2E1 forward primer CTC G G A TC C A C A TTC TTG G C G G A C TTC G C G A
Bold print represents BamHI restriction site.
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Tissues exhibiting differences between tailed and nontailed samples, indicating 
potential Pgp2 mRNA degradation product(s) underwent another PCR reaction with 
unlabeled forward primer and were ran on a
1.5% ethidium bromide stained agarose gel with 0.5 X TBE buffer. The gel was visualized 
using Chemilmager™ System. The potential product(s) was then excised from the gel using 
a sharp scalpel under UV light, and gel purified using QIAEX II Gel Extraction Kit 
(QIAGEN, Mississauga, ON). Two pL of the purified sample then was used for 6 PCR 
reactions and included the following reagents: 3.5 pL of lOX PCR Buffer; 3.5 pL of 2.5 mM 
dNTPs; 1 pL 50 mM MgCla; 5 pL (100 ng/pL) of EEl forward primer; 1 pL of reverse Oligo 
dTig-XhoI (100 ng/pL) primer ; I pL of Taq Polymerase (5 U/pL); and ddHzO to make the 
final reaction volume up to 35 pL. The PCR products were pooled together totaling a final 
volume of 210 pL. Two volumes of 100% ethanol and I/IO'*’ the volume of 3 M NaOAc pH 
5.2 was added and the solution was mixed thoroughly and precipitated at -20°C for 24 hr s. 
The solution was removed and centrifuged for ten minutes at 12,000 rpm. The supernatant 
was removed and the DNA pellet was washed by gently adding 200 pL of 70% cold ethanol. 
The sample was then centrifuged for 5 minutes and the supernatant was aspirated. The DNA 
pellet was resuspended in 7 pL of ddHaO and was loaded on a 1.5% ethidium bromide 
stained agarose gel. Again the potential product(s) were excised from the gel and purified. 
The purified sample was then used to perform ligation and transformation experiments in an 
attempt to sequence the potential degradation product(s).
3.0.3 Preparation of Competent Cells
DH5-a competent cells required for transformation, were then prepared via the
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following methodology: 10 i^L of frozen stock DH5-a cells were added to 3 mL Luria- 
Bertani (LB) broth in a sterile 15 mL tube and incubated at 37°C overnight with agitation. 
Ten |iL of this culture was transferred to a flask containing 50 mL LB broth and was again 
incubated at 37°C with agitation until the OD reached 0.3 (2 hours) at 600 nm. The culture 
was then centrifuged for 10 minutes at 2,500 rpm and the supernatant was removed. The 
pellet was resuspended in 3.5 mL of cold 50 mM CaCl2 and the volume was increased to 25 
mL. The cells were then placed on ice for 30 minutes and then centrifuged at 2,500 rpm for 
10 minutes. The supernatant was again removed and the competent cells were resuspended 
in 3.5 pL of cold 50 mM CaClz.
3.0.4 Ligation of Putative Pgp2 mRNA degradation products.
To prepare for the ligation of the potential product(s) it was necessary to perform a 
restriction digest on both the purified product and pGEM7Zf(+) cloning vector (Fig. 3.1.). 
All of the gel purified product (20 pL) was added to the restriction digest, which included the 
following reagents: 6 pL of BamRV, 6 pL of Xhol; 3.6 pL of lOX double digest buffer; and 4 
pL of dd H20. The solution was incubated at 37°C for 3 hours. ddHzO was added to make a 
final colume of 100 pL, and standard ethanol precipitation was performed. The pellet was 
resuspended in 10.5 pL of ddHiO. The resuspended product was added to 1 pL of digested 
pGEM7Zf(+) vector (Figure 3.3.) and the following reagents were added: 3 pL of T4 DNA 
Ligase (400 LF/pL) (New England Biolabs); and 1.45 pL of 10 X Ligase Buffer (New
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England Biolabs). The reaction mixture was incubated at 4°C for 24 hours.
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Figure 3.3. pGEM7Zf(+) cloning vector used in ligation reaction (Promega, Madison, WI).
3.0.5 Transformation and Plating
In a prechilled sterile tube all of the ligation mix was added to 200 pL of DH5-a 
competent cells. The mixture was stored on ice for 30 minutes and then heat shocked at 
42°C for 2 minutes. One pL of LB Broth was added and the reaction was incubated at 37°C 
for 30 minutes with agitation. 2pL of isopropyl b-D-thiogalactoside (IPTG) and 50 pL of 5- 
bromo-4-chloro-3- indolyl- beta- D- galactopyranoside (X-GAL) were added and the mixture 
was poured on a pre-warmed agar plate. The plate was incubated at 37 °C with the lid 
partially off in order for the solution to dry for 20 minutes and then inverted. After 24 hours 
10 white colonies were picked with a sterile pipette tip, and then placed in a sterile tube 
containing 3 mL LB broth and 1.5 pL 50 mg/mL ampicilin. The cultures were grown 
overnight at 37°C with agitation.
To determine if any of the white bacterial colonies positively contained an insert that 
might be a possible degradation product it was necessary to purify the plasmid DNA from the 
rest of the culture. The QIAprep Spin Miniprep Kit (QIAGEN) was used for this procedure 
and yielded a 50 pL sample of purified plasmid DNA.
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3 jxL of purified plasmid sample then underwent a restriction digest with 1 pL of 
Xhol, IpL of BamHI, 1 pL of lOX Double Digest Buffer, and 4 pL ddH20. The reaction 
mixture was incubated for 1 hour at 37°C and then ran on a 1.5% ethidium bromide stained 
agarose gel. The gel was visualized using ChemilmagerTM System.
3.0.6 Dideoxy Sequencing of Putative Degradation Product(s)
Sequenase Version 2.0 DNA Sequencing Kit (United States Biochemical, Cleveland, 
OH) was used to sequence purified plasmid samples that contain an insert. The protocol is as 
follows: 5 pL of purified plasmid sample for clones J l , J2, J7, and JIG was added to 15 pL 
of ddHaO. 2 pL of 2 M NaOH, 2 mM EDTA mix was added and the solution was incubated 
at 80°C for 5 minutes in order to hydrolyze any RNA that may be present. ddH20 was added 
to increase the volume of the solution to 100 pL. Standard ethanol precipitation was 
performed and the pellet was resuspended in 7 pL of ddH20. To the DNA, 2 pL of 
sequencing buffer and 10 ng of 7Z-T7 primer was added. The solution was mixed and 
incubated at 37°C for 15 minutes. The following was then added to the DNA solution: IpL 
of 100 mM DTT; 2 pL of diluted dGTP labeling mix (1:20 with ddH20); 1 pL of 1 mM 
MnCU; 1 pL ^^S-dATP (lOpCi/pL) (Amersham Biosciences Corp.), and 2 pL Sequenase™ 
(1:10 dilution with TE). The mixture was left at room temperature for 3 minutes. 3.5 pL of 
labeling reaction mix was then added to four separate microcentrifuge tubes, each containing 
2.5 pL of a different dideoxy triphosphate. The solutions were incubated at 37°C for 5 
minutes and 4 pL of Stop Solution was added. The sequencing reaction for Clones J6 and J9 
required the use of all purified plasmid sample (45 pL) as the concentration of these plasmid 
samples were lower than the others. The amount of reagents used for these two samples 
doubled in all respects.
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Prior to loading on an 8% polyacrylamide/ 7 M urea sequencing gel, the solutions 
were incubated at 80°C for 2 minutes, and then quickly placed on ice. The sequencing gel 
was also pre-loaded with Formamide Loading Solution to ensure the lanes were not leaking. 
The gel was ran for 30 minutes at 60 W constant current to pre-warm it. After the samples 
were loaded, the gel was ran at 60 W constant current until the blue dye of the stop solution 
reached the very bottom of the gel (approximately 1.5 hours). The gel was then dried and 
exposed for 48 hours. The image was scanned using Cyclone phosphorimager and visualized 
using OpiQuant software.
Results 3.1
3.1.4 Detection of degradation products in Liver and Tumour tissue samples 
using Yeast Poly (A) Polymerase RT-PCR method.
The detection of putative Pgp2 mRNA degradation intermediates in total RNA from 
normal liver and liver tumour from three different animals involved using the Yeast Poly (A) 
tailing RT-PCR method. In order to detect potential degradation products it was necessary to 
include nontailed-RT-PCR products, as presence of bands in tailed samples that were absent 
in nontailed samples would indicate the existence of potential decay products. The analysis 
of normal liver and liver tumour tissue samples for putative Pgp2 mRNA decay products 
involved the use of five different forward primers (see Figure 3.2.) ensuring that the entire 
Pgp2 mRNA sequence was analyzed. Samples of tailed and nontailed in-vitro transcribed 
RNA corresponding to the region under study were also included as verification that the 
Yeast Poly (A) tailing RT-PCR method was employable.
Analysis of liver tissue samples with forward primer 2A (Figure 3.4) was carried out
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on an ethidium bromide stained 1.5% agarose gel. Several bands are noticed in both the 
tailed and nontailed samples (lanes 5, 7, 8, and 9), however, there is no significant 
differences present between tailed and nontailed samples. There were PCR products 
present/detected in tailed samples that correspond to in-vitro transcribed Pgp2A. This 
sample exhibits two distinct bands, one of approximately 1 kb, while Pgp2A nontailed 
sample exhibits several. The 1 kg fragment likely corresponds to the Pgp2A RNA size. 
Differences are noted between tailed and nontailed in-vitro transcribed Pgp2A RNA, 
indicating that the Yeast Poly (A) tailing RT-PCR method was successfully applied.
Analysis of tumour samples with forward primer 2A was carried out on a 6% 
denaturing polyacrylamide/urea gel (Figure 3.5.). Again, there are no differences between 
tailed and nontailed tumour samples detected. Similar results were obtained with in-vitro 
transcribed Pgp2A RNA. The tailed sample exhibits two distinct bands (lane 2), while 
Pgp2A nontailed sample exhibits several (lane 3). As with normal liver samples (Figure 3.4.), 
no distinct PCR products were seen in tailed tumour samples versus nontailed samples 
(Figure 3.5., lanes 4-9).
Analysis of liver and tumour samples with forward primer 2B1 was carried out on a 
6% denaturing polyacrylamide/urea gel and results are shown in Figure 3.6. As seen in 
Figure 3.6. there are no differences between tailed and nontailed normal liver and liver 
tumour tissue samples present (lanes 4-15). In-vitro transcribed Pgp2B 1 tailed sample 
exhibits one band of approximately 1 kb, while Pgp2B 1 nontailed sample exhibits several. 
The presence of tailed in-vitro transcribed PCR products (lane 2) indicate that the Yeast Poly 
(A) tailing RT-PCR method was successful.
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Analysis of liver samples (Figure 3.7.) and tumour samples (Figure 3.8.) with forward 
primer 2C were carried out on ethidium bromide stained 1.5% agarose gels. There are no 
significant differences between tailed and nontailed tissue samples in both normal liver (see 
Figure 3.7., lanes 4-9) and liver tumour (see Figure 3.8., lanes 4-9). In tailed samples of both 
normal liver (lanes 4, 6, and 8) and liver tumour (lanes 4, 6, and 8), a small smear was 
observed near the well. Curiously, this smear was also present in tailed in-vitro transcribed 
RNA (lane 2). Due to its presence in all tailed samples, this smear was not further 
investigated as a putative degradation product. In-vitro transcribed Pgp2C tailed sample 
exhibits one distinct band approximately 1 kb in size, while Pgp2C nontailed sample exhibits 
several (Figure 3.7. and 3.8., lanes 2 and 3), again indicating that the Yeast Poly (A) tailing 
RT-PCR method was again successful in detecting in-vitro transcribed RNA.
Analysis of liver and tumour samples with forward primer 2D was also carried out on 
a 1.5% ethidium bromide stained agarose gel (Figure 3.9.). There were no differences 
between tailed and nontailed tissue samples present (lanes). In-vitro transcribed Pgp2D 
tailed sample exhibits one distinct band (lane), while Pgp2D nontailed sample exhibits 
several (lane). Once again, the differences present in tailed and nontailed in-vitro transcribed 
Pgp2D RNA samples indicate that the Yeast Poly (A) tailing RT-PCR method was 
successfully employed.
PCR products of normal liver and liver tumour samples with 2E1 forward primer 
were both analyzed on a 6% denaturing polyacrylamide/urea gel (Figure 3.10. and 3.11. 
respectively). Distinct differences are present between the tailed samples of both tissue 
samples (Figure 3.10. and 3.11., lanes 4-9). In tailed liver samples (Figure 3.10., lanes 4, 6, 
and 8) a smear is present from approximately 500 bp to approximately 181 bp in all three
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tissue samples. This smear is not present in nontailed samples (lanes 5, 7, and 9). In tailed 
liver tumour samples a very intense smear is present from approxiamtely 439 bp to 
approximately 181 bp in two tissue samples (Figure 3.11., lanes 6 and 8). In-vitro 
transcribed PgpEl tailed sample exhibits one very intense distinct band approximately 1 kb 
in size (lane 2), and four faint bands, while Pgp2El nontailed sample exhibits several bands 
(lane 3). The distinct band of approximately 1 kb likely corresponds to in-vitro transcribed 
RNA indicating that the Yeast Poly(A)tailing method was used successfully in this 
experiment.
Liver and tumour samples with 2E1 forward primer were then ran on an ethidium 
bromide stained 1.5% agarose gel (Figure 3.12. and 3.13. respectively) to determine if further 
analysis of these potential Pgp2 mRNA degradation products could proceed without the use 
of radioactive material. Consistent with analysis on the 6% denaturing polyacrylamide/urea 
gel (Figure 3.10.), tailed normal liver samples exhibit a smear around the 500 bp size in all 
three tissue samples (lanes 4, 6, and 8). Nontailed samples do not have a smear present, but 
one distinct band at approximately 1000 bp (lanes 5, 7, and 9). Tailed tumour samples also 
exhibit the same smear (lanes 6 and 8) when ran on a 1.5 % agarose gel (Figure 3.13.) which 
is consistant with results obtained from 6% denaturing polyacrylamide/urea gel analysis 
(Figure 3.11.). Nontailed samples have 2 bands at approximately 1000 and 506 bp that are 
present in Tumour 0.1 and Tumour 0.2 (lanes 5 and 7).
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Figure 3.4. Liver samples analyzed with Pgp2A forward primer on a 1.5% 
agarose gel. Prior to amplification with Pgp2A forward primer, liver samples 
were either tailed and reverse transcribed (even lanes), or reverse transcribed 
(odd lanes) to search for putative Pgp2 mRNA degradation intermediates. 
Pgp2A cDNA control is 799 base pairs (bp) long.
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Figure 3.5. Tumour samples analyzed with Pgp2A forward primer on a denaturing 6% 
polyacrylamde/7M urea gel. Prior to amplification with Pgp2A forward primer, liver 
samples were either tailed and reverse transcribed (even lanes), or reverse transcribed (odd 
lanes) to search for putative Pgp2 mRNA degradation intermediates. Pgp2A cDNA control 
is 799 bp long. The marker used was pBR322 cut with the restriction enzyme Hae II.
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Figure 3.6. Liver and tumour samples analyzed with Pgp2Bl forward primer on a 
6% denaturing polyacrylamde/7M urea gel. Prior to amplification with Pgp2Bl 
forward primer, samples were either tailed and reverse transcribed (even lanes), or 
reverse transcribed (odd lanes) to search for putative Pgp2 mRNA degradation 
Intermediates. Pgp2Bl cDNA control Is 800 hp long. The marker used was pBR322 
cut with the restriction enzyme Hae II.
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Figure 3.7. Liver samples analyzed with Pgp2C forward primer on a 1.5 % 
agarose gel. Prior to amplification with Pgp2C forward primer, samples 
were either tailed and reverse transcribed (even lanes), or reverse 
transcribed (odd lanes) to search for putative Pgp2 mRNA degradation 
intermediates. Pgp2C cDNA control is 800 hp long.
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Figure 3.8. Tumour samples analyzed with 2C forward primer on a 1.5% 
agarose gel. Prior to amplifîcation with Pgp2C forward primer, samples 
were either tailed and reverse transcribed (even lanes), or reverse 
transcribed (odd lanes) to search for putative Pgp2 mRNA degradation 
intermediates. Pgp2C cDNA control is 800 bp long.
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Figure 3.9. Liver and tumour samples analyzed with Pgp2D forward 
primer on a 1.5% agarose gel. Prior to amplification with Pgp2D forward 
primer, samples were either tailed and reverse transcribed (even lanes), 
or reverse transcribed (odd lanes) to search for putative Pgp2 mRNA 
degradation intermediates. Pgp2D control is 800 bp long.
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Figure 3.10. Liver tissue samples analyzed 
with Pgp2El forward primer on a 6% 
denaturing polyacrylamide gel. Prior to 
amplification with Pgp2El forward primer, 
samples were either tailed and reverse 
transcribed (even lanes), or reverse 
transcribed (odd lanes) to search for 
putative Pgp2 mRNA degradation 
intermediates.Pgp2El control is 1048 hp 
long. The marker used was pBR322 cut with 
restriction enzyme Hae II.
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Figure 3.11. Tumour tissue samples 
analyzed with Pgp2El forward primer 
on a 6% denaturing polyacrylamide gel. 
Prior to amplification with Pgp2El 
forward primer, samples were either 
tailed and reverse transcribed (even 
lanes), or reverse transcribed (odd lanes) 
to search for putative Pgp2 mRNA 
degradation intermediates.Pgp2El 
control is 1048 bp long. The marker 
used was pBR322 cut with restriction 
enzyme Hae 11.
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Figure 3.12. Liver tissue samples 
analyzed with 2E1 forward primer 
on a 1.5% agarose gel. The same 
Poly (A) tailed and nontailed 
samples from Figure 3.10. were 
analyzed to determine if further 
analysis could he accomplished 
without the use of radioactive 
material.
Figure 3.13. Tumour tissue samples 
analyzed with 2E1 forward primer 
on a 1.5% agarose gel. The same 
Poly (A) tailed and nontailed 
samples from Figure 3.10. were 
analyzed to determine if further 
analysis could he accomplished 
without the use of radioactive 
material.
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3.1.5 Gel Purification and Secondary PCR of Liver samples with 2E1 Forward 
Primer.
To confirm specificity of the smear observed in normal liver and liver tumour tailed 
samples, the smear observed in liver samples analyzed with Pgp2El forward primer were 
excised for the gel and purified (see Methods 3.0.2). Secondary PCR was also performed 
using the purified products as a template. The secondary PCR products were ran on a 1.5% 
agarose gel to check if the putative degradation products were successfully purified and 
amplified (Figure 3.14.). All purified secondary PCR liver tissue products exhibit a smear 
from approximately 600 bp to 250 bp, suggesting that the smear is specific. Putative 
degradation product(s) present in Liver 0.1 were used in further experiments to determine if 
the PCR product(s) belong to Pgp2 mRNA.
1018-
506-
298-
Figure 3.14. Gel purifîed, secondary PCR products from tailed liver 
samples on a 1.5% agarose gel. Smears identified in Figure 3.12. were 
excised and purified. Purified samples underwent secondary PCR with 
the same primers to determine the specificity of the smears.
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3.1.6 Preparation of pGEM7Zf(+) Plasmid Vector for Ligation with Putative 
Degradation Products.
Plasmid vector pGEM7Zf(+) underwent a linearization reaction with restriction
enzymes BamYll and Xhol (Figure 3. 15.). The circular structure of the intact plasmid
molecule appears as two bands after gel electrophoresis. The major band (approximately
2036 bp) is the plasmid DNA, whereas the top band represents residual chromosomal and
nicked plasmid DNA. Complete digestion of the pGEM7Zf(+) plasmid is noted as only 1
band is present in the sample that was digested with BamHI and Xhol.
T
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Figure 3.15. pGEM7Zf(+) plasmid 
linearized with restriction enzymes 
BamHI and X ho\ in preparation for 
ligation reaction on a 1.5% agarose gel. 
Lane 2 exhibits undigested plasmid, and 
lane 3 shows digested plasmid sample.
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PCR products (see Results section 3.1.2) which are putative Pgp2 mRNA degradation 
intermediates were purified and digested with BamYU. and Xhol, and then ligated into 
linearized pGEM7Zf(+) plasmid (see Method 3.0.4). The ligated reaction mixture was then 
transformed into DH5-a competent cells (See Method 3.0.5).
3.1.4. Selection of Bacterial Colonies Positive for Insert and Miniprep of Positive 
Colonies.
White and blue colonies were present on agar plates plated with transformed DH5-a 
competent cells. Colonies that are positive for the inserted putative degradation product(s) 
are coloured white. Colonies that do not contain an insert are coloured blue. Ten white 
colonies were picked and grown in liquid medium overnight (See Methods 3.0.5). The ten 
plasmid DNA samples were then isolated and subjected to a restriction digest with BamHI 
and Xhol. Digested plasmid samples were ran on an ethidium bromide stained 1.5% agarose 
gel (Figures 3.16. and 3.17.) to check for the presence of an insert (See Methods 3.0.5). 
Figure 3.16. shows results of elones J l to J5 after restriction digest with BamHI and Xhol. 
Clone J l exhibits 2 distinct bands after digestion with BamHI and Xhol (lane 2). The top 
band represents linearized plasmid DNA, and the second band is approximately 500 bp in 
size. Clone J2 exhibits 3 bands after digestion (lane 3); the top band again representing 
plasmid DNA, and two additional bands approximately 506 bp and 220 bp in length. Clones 
J3, J4, and J5 exhibit only plasmid DNA after the restriction digest (lanes 4, 5, and 6).
Figure 3.17. exhibits clones J6 to JIO after a restriction digest with BamHI and Xhol. 
Clones J6, J7, J9, and JIO all exhibit two bands (lanes 2, 3, 5, and 6), the top band 
representing linearized plasmid DNA, and the second band approximately 506 bp in size . 
Clone J8 exhibits plasmid DNA only. Clones J l, J2, J6, J7, J9, and JIO, deemed to contain
60
inserts were subjected to sequence analysis (see Methods 3.0.5) Samples containing only 
plasmid DNA after digestion were disregarded and not used in further experiments.
Figure 3.16. Plasmid clones J1-J5 on a 1.5% 
agarose gel. Clones (lanes 2-6) underwent 
restriction digest with enzymes BamHI and Xhol 
to check for the presence of an insert.
1018-
1 2 3 4 5 6
Figure 3.17. Plasmid clones J6-J10 on a 1.5% 
agarose gel. Clones (lanes 2-6) underwent 
restriction digest with enzymes BamHI and Xhol 
to check for the presence of an insert.
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3.1.5 Dideoxy Sequencing and Blast Search of Potential Degradation Product(s)
Clones J l , J2, J6, J7, 19, and JIO were manually sequenced (see Methods 3.0.4) to 
determine if they contained an insert that was a possible Pgp2 mRNA degradation product 
(See Figure 3.18.). All clones contained the multiple cloning site sequence from the vector 
pGEM7Zf(+). Sequences for clones J l ,  J6, J9, and JIO revealed an identical sequence that 
was different from the vector sequence. This sequence was subjected to a nucleotide BLAST 
search on the National Center for Biotechnology Information website 
(http://www.ncbi.nlm.nih.gov/) to determine if they were Pgp2 mRNA degradation products. 
The nucleotide search provided no significant matches. The sequence determined for clone 
J2 also contained vector sequence and a potential inserted sequence that was unique. This 
sequence was also subjected to a nucleotide BLAST search that yielded no significant results. 
This was also the case for clone J7 that again contained the vector sequence plus a potential 
insert. In conclusion, no Pgp2 mRNA degradation products were detected.
Table 3.2 Sequences of clones identified to contain an insert
C lone Sequence *
J l 5 ’... GCCGGGGTCGCGAAGTCCGTTAAGATGGGATCCAAGCTTATCGATTTCGAACCCG 
G G G T A C C G A A T T C C T C G A G C .. .3 ’
J2 5 '. . .  TCA G CA TG CTCC TC TAG A CTC GA G CC GG G G TATA TA GC CTTTGA A CA A CG G TAG C 
TAGTTTCTAGGCATTCTTTGTCCCTTCCTAACCTCTTGTGCTCGCTGAGACAATTGCCAG 
TGTCGC AGTCTA A G G ,.. 3 ’
J6 5 ’G CA TG CTCC TC TAG A CTC GA G CC GG G G TCG CG A AG TCC G CCA A G ATG G G ATC CA AG C 
TTATCGA TTTCG A ACCCGG G G TA CCG A ATTCCTCG A G G A TT... A G AGCTCCCAACGCGTT 
G G A TG CA TA G C TTG A G TA .. .3 ’
J7 5 ’CC TCTA GA C TC G AG G A ATTCG G TTGA C CCC G GG TTCG A AA A TCC G A TA A GC TTG G A TC 
A A GC TTA TCG A TTCG A CC.. ..3 ’
J9 5 ’ GC ATGCTCCTCTAG A CTCG A G CCG G G G TC G CG A A G TCC G C CA A G  ATGGG ATCCAAGC 
TTA TCGA TTTCG A ACCCGG G G TACCG A ATTCCTCG A GG A TT.. .AGAGCTCCCAA CGCGTT 
G G A TG CA TA G C TTG A G TA .. .3 ’
JIO 5’CC TCTA GA C TC G AG G A A TTCG G TTGA C CCC G GG TTCG A AA A TCC GA TA A GC TTG G A TC 
A A GC TTA TCG A TTCG A CC.. ..3 ’
' X hol restriction site
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Figure 3.18. An example of nucleotide 
sequences derived from dideoxy 
sequencing method (see Methods 3.0.5). 
The Nucleotide sequence of clones J2 
(left) and J l (right) on an 8% 
denaturing polyacrylamide/urea gel.
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Discussion 3.2
The main objective of this chapter was to use the Yeast Poly (A) tailing RT-PCR 
method to detect Pgp2 mRNA degradation products in vivo. Results using in-vitro 
trasnscribed RNA (Pgp2A-2El) have shown that RNA can be tailed and amplified using this 
method. Analysis of tailed and nontailed normal liver and liver tumour samples amplified 
using five specific forward primers that covered the entire length of Pgp2 mRNA was carried 
out on both denaturing 6% polyacrylamide gels and 1.5% agarose gels. Analysis using 
forward primers 2A, 2B1, 2C, and 2D yielded no detection of putative degradation 
intermediates. This is consistent with data retrieved using ligation-mediated PCR (Lee et ah, 
unpublished results) Analysis of normal liver and liver tumour tissue samples with 2E1 
forward primer revealed a large smear present in tailed samples, that was absent in nontailed 
samples (Figure 3.10. and figure 3.11.). This also was consistent with results obtained from 
ligand-mediated PCR (Lee et ah, unpublisbed data). The presence of the smear indicated the 
presence of putative Pgp2 mRNA decay intermediate(s), and required further investigation to 
confirm this.
In summary, although it appeared it appeared that the Yeast Poly (A) tailing RT- 
PCR method was successful in detecting in-vitro RNA, detection of specific tailed RNA in 
vivo posed a problem. To recap, a smear was present in tailed samples and absent in 
nontailed samples. This was detected in both normal liver and liver tumours analyzed with 
EFl forward primer only. These results were reproducible and PCR products could be 
reamplified using the same primers (Figure 3.14.). It was also possible to clone amplified 
fragments into pGEM7Zf+ vector (Figure 3.16. and figure 3.17.). This strongly suggested 
that the insert contained both BamHI and Xhol restriction sites, consistent with a putative
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Pgp2 mRNA decay product amplified with 2E1 forward primer containing a BamHI site, and 
an Oligo dTis-XhoI reverse primer containing an Xhol site. Surprisingly, sequence analysis 
revealed that inserts in all positive clones were not that of Pgp2 mRNA. To understand this 
phenomenon, a few points must be considered. Firstly, the specificity of the Oligo dTig- 
Xhol primer must be taken under consideration. This primer is nonspecific as it consists of a 
stretch of T bases. Due to its nonspecific nature, the OligodTig-XhoI primer can hybridize to 
any stretch of A bases.
A second point that needs consideration relates to the samples used. The samples 
used to search for Pgp2 mRNA decay intermediates were total RNA samples isolated from 
liver and tumour. This means that not only did the samples contain possible degraded Pgp2 
mRNA, but also various other RNAs. One would think that forward primer 2E1 would be 
specific for Pgp2 mRNA. However, based on the amplification and sequencing of products 
that are not Pgp2 mRNA, it is possible that the Pgp2El primer is not specific for only Pgp2 
mRNA. A nucleotide BLAST search was performed on the 2E1 forward primer sequence, 
however no significant matches were made other than with Pgp2 mRNA. This result is not 
surprising though, as the sequences determined contained no significant match after a 
nucleotide BLAST search either. The sequence of 2E1 forward primer was not detected in 
sequence analysis, however, manual sequencing only enables reading of the sequence up to a 
certain point before it becomes illegible. The specificity of 2E1 forward primer is 
questionable, and can not definitively be ruled out as a possible explanation as to why this 
method failed in detecting Pgp2 mRNA decay intermediates in vivo.
The success of this experiment was also concentration dependant. As previously 
stated, the concentration of Pgp2 mRNA decay products is unknown. It is possible that
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putative Pgp2 mRNA decay products were successfully poly (A) tailed and amplified, 
however, the concentration of successfully amplified decay products had to have been lower 
than the fragments that were detected. It is also possible that decay product(s) were not poly 
(A) tailed due to low abundance, however this is unlikely as a decay intermediate was 
identified using ligation-mediated PCR, which is less sensitive than the Yeast Poly (A) 
Tailing RT-PCR method in detecting in-vitro RNA (Lee et al., unpublished results). It is 
likely that the nonspecific nature of the Oligo dTig-XhoI primer, coupled with probable low 
concentration of decay intermediates and a possible conserved Pgp2El forward primer 
region within another gene were the root causes as to why Pgp2 mRNA decay intermediates 
were not detected.
As previously stated, all determined sequences did not have a significant match when 
a nucleotide BLAST search was performed. All one can say regarding the fragments cloned, 
is that they are located in similar tissue samples as Pgp2 mRNA. Another interesting feature 
pertaining to the sequencing results, is that one would expect to have a string of T bases at 
the 5’ end of the sequence. This result however, is not present. It is likely that an Xhol 
restriction site was present upstream from the region where the Oligo dTig-XhoI primer 
hybridized to. This would explain the presence of the Xhol restriction site in all sequences 
determined, and a lack of T bases (See Table 3.2).
Detection of decay intermediates in vivo has previously been reported. Albumin 
mRNA degradation products have been identified in vivo using ligation-mediated PCR 
(Hanson and Schoenberg, 2001). This method involves the annealing of a specific primer to 
the hydroxyl terminus of decay products, followed by amplification using two specific 
primers. This method has also been used to successfully identify a Pgp2 mRNA decay
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intermediate (Lee et al., unpublished results; See Chapter 4 and 5 for discussion). Taken 
together, it is concluded that primer specificity is very critical for specific amplification of 
degradation products. This study failed to detect Pgp2 mRNA decay products in vivo.
Chapter 4
Using Primer Extension Method to determine the Nature of Nucleolytic (Exonucleolytic
or Endonucleolytic) Cleavage
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As previously mentioned (Chapter 3, Discussion 3.2) an mRNA degradation product 
belonging to Pgp2 was identified using ligation-mediated PCR. This method was first 
described in the identification of albumin mRNA decay intermediates in vivo (Hanson and 
Schoenberg, 2001). The ligation-mediated PCR protocol is useful in detection of mRNA 
decay intermediates that possess 3’ hydroxyl termini. A DNA ligation primer that has a 5’- 
phosphate and a 3’- amino group is ligated to the decay intermediate using RNA ligase. 
Reverse transcription is performed with a complementary primer, and the cDNA is amplified 
using specific primers (Hanson and Schoenberg, 2001). A Pgp2 mRNA decay intermediate 
was identified using this method and amplified with Pgp2El forward primer. This product 
was confirmed to be a Pgp2 mRNA decay product through sequence analysis (Lee et al., 
unpublished results). It was then necessary to determine if the product was the result of 
endonucleolytic cleavage.
Primer extension is an accurate assay used to map in vivo endonuclease cleavage 
sites. This experiment is able to identify unique cleavage sites that will appear as bands that 
correlate with the exact position where the polymerase runs off the template. Cleavage sites 
are distinct from polymerase pausing sites, which are identified in the primer extension 
performed on an in vitro control transcript. A DNA sequencing ladder is also included in the 
analysis to enable precise identification of the cleavage sites. The methodology for this 
experiment was derived from a detailed review of experiments related to the characterization 
of mRNA endoribonucleases (Schoenberg & Cunningham, 1999).
This chapter describes the use of Primer Extension method to determine the nature of 
cleavage of putative Pgp2 mRNA degradation product(s). Results and discussion related to 
the nature of decay of 5 ’ end Pgp2 mRNA degradation products in normal liver and liver
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tumour are included. A discussion regarding possible mechanisms for increased Pgp2 mRNA 
stability is also included.
Methods 4.0
4.0.1 Primer Extension
Based on results from ligation-mediated PCR, primer RP 
5’CGTGAATGACGCTGGGGAGCTCAACACC3’ was designed 50 nucleotides 
downstream from the detected degradation product by ligation-mediated PCR (Figure 4.1).
AllGntlOJ llQ\(nt3933)
■S' I I ,
Pri mer RP (nt 591 - nt é l 9)
V2 eiem%esiie
idbntified % LMfCR 
{see Discussion
Figure 4.1 Location of Primer RP in relation to previously identified Pgp2 degradation product (Lee et 
al., unpublished data) for use in primer extension experiment. V2 cleavage site is located at 541 nt.
RP primer was 5’ labeled with y^^P-ATP and then used for PCR reaction described 
below (see Methods 2.0.3). Standard ethanol precipitation (see Methods 2.0.1) was 
performed on 3 pL of 5’ y^^P-ATP labeled primer with 10 pg of total RNA samples extracted 
from liver 0.1, 0.2 and tumour 0.1, 0.2. As a control, the same amount of 5’ labeled primer 
with 20 ng of in-vitro transcribed Pgp2El RNA also underwent standard ethanol 
precipitation. The RNA pellets were resuspended in 10 pL of annealing buffer (50 mM Tris- 
HCl; pH 8.7; 0.54 M KCl; and 1 mM EDTA), and incubated at 65°C for 10 minutes, 54°C 
for 90 minutes and slowly cooled to room temperature. 30 pL of Reverse Transcription
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mixture (10 mM dATP, dCTP, dGTP, dTTP; 0.25 M Tris-HCl, pH 8.7; 65 mM MgCb; 0.1 
M DTT; MMLV reverse transcriptase; ddHaO) was added to each sample and the mixture 
was incubated for 1.5 hours at 42°C. The reaction was stopped by an addition of 260 pL of 
NET buffer (0.3 M NaAc; 10 mM Tris-HCl, pH 8.0; 1 mM EDTA) and 600 pL of cold 100% 
ethanol. The samples were precipitated at -20°C for 30 minutes and centrifuged for 10 
minutes at 12,000 rpm. The pellets were washed with 200 pL of 70% cold ethanol and 
centrifuged for an additional 5 minutes. The supernatant was removed and the pellets were 
allowed to air dry for 15 minutes. The pellets were resuspended in 4 pL of formamide 
loading buffer, boiled for 5 minutes and placed on ice prior to loading on an 8% 
polyacrylamide/7 M urea sequencing gel.
Dideoxy Sequencing (see Methods 3.0.4) was carried out on pGEM4Z-Pgp2El 
plasmid with y^^P-ATP 5’ labeled primer extension primer with the following changes: After 
standard ethanol precipitation the pellet was resuspended in 5 pL of ddH20 and ^^S-dATP 
was not used as a labeled primer was utilized.
Samples from the Primer Extension and Dideoxy Sequencing experiments were ran at 
60 W constant current on a pre-ran 8% polyacrylamide/7 M urea sequencing gel for 
approximately 1.5 hours. The gel was dried and exposed as previously described (see 
Methods 3.0.4).
Results 4.1
Primer extension is an accurate assay for mapping endonucleolytic cleavage sites. 
The presence of bands potentially indicates cleavage sites where the polymerase runs off the
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template. Cleavage sites are distinet from polymerase pausing sites, which are identified in 
the primer extension performed on in vitro transcribed Pgp2El RNA transcript. The 
cleavage site positions were determined relative to a DNA sequencing ladder prepared from 
pGEM4Z-Pgp2El plasmid.
This experiment was performed based on results from section 3.1.4, and due to the 
successful detection and sequencing of a Pgp2 mRNA degradation product present in both 
liver and tumour tissue samples using ligation-mediated PCR with Pgp2El forward primer 
(Lee et al., unpublished data). The primer extension experiment revealed 5 cleavage sites, 
one of them consistent with the ligation-mediated PCR detected degradation product (See 
Figure 4.2. and 4.3. lanes 5, 6, 7, and 8). For simplicity, the cleavage site related to the 
detected decay intermediate identified by ligand-mediated PCR, is termed V2. All cleavage 
sites detected were present in both liver and tumour tissue samples (see Figure 4.2., lanes 5, 
6, 7, and 8).
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Figure 4.2. Primer extension analysis of liver and tumour tissue samples. Left picture details entire 
length of experiment. Right picture details important information pertaining to endonucleolytic cleavage 
sites present in hoth liver and tumour.
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Site 1 Site 2 Site 3
'i ' '1 ' '1 '
5’ TGGAAAAAC TTGCCTAA CTGTGTATT7TTGTGTTCCAG
Site 4 V2 Site
CCAGCTGCCAGGCACCA AA GTGAAACCTGG ATGTGGC
Site 5
AA CAATAGCCCGCACCAATCCGGTT 3’
Figure 4.3. Locations of identified cleavage sites in Pgp2 mRNA sequence from primer extension analysis 
(see figure 4.2.).
Discussion 4.2
Based on findings from primer extension analysis it can be concluded that the Pgp2 
mRNA degradation product previously identified by ligation-mediated PCR is the result of 
endonucleolytic cleavage. Aside from the V2 cleavage site, five major cleavage sites were 
also identified and were present in both liver and tumour. These sites appear very intense in 
comparison to the V2 cleavage site, indicating that the V2 cleavage site is a minor site. Why 
then was it not possible to detect degradation products that parallel these major sites? A 
possible explanation as to why this was not possible requires investigation into the general 
process of mRNA decay and into the process of how ligation-mediated PCR detects decay 
products. mRNA degradation products can be of two natures in regards to their 3’ end; the 
3’ terminus can either have a phosphate or hydroxyl group. As previously described, 
ligation-mediated PCR employs the use of a specific primer, which is ligated to hydroxyl
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termini of decay intermediates (Hanson and Schoenberg, 2001). Therefore, this method, as 
well as the Yeast Poly(A) tailing RT-PCR method can only detect decay intermediates with 
hydroxyl termini. It is possible that the major cleavage sites demonstrated in primer 
extension analysis represent products with phosphate termini, which could not be detected 
using ligation-mediated PCR or Poly (A) tailing method. Presently, there is no method 
available to detect mRNA decay products with 3’ phosphate termini in vivo. However, such 
possibility would require further investigation.
Identification of the decay intermediate by ligation-mediated PCR in both liver and 
tumour, and the identification of the exact same cleavage sites by primer extension analysis 
indicate that the decay pathway of Pgp2 mRNA is the same in hoth liver and tumour. This 
result is significant as it demonstrates that increased mRNA stability exhibited in tumours 
(Lee et ah, 1998) is not likely related to endonucleolytic decay of Pgp2 mRNA between 
normal liver and liver tumour. This suggests that one should examine possible differences in 
deadenylation and 3’-5’ decay.
In conclusion, this experiment identified that endonucleolytic cleavage plays a role in 
the decay process of Pgp2 mRNA in vivo. The mode whereby Pgp2 mRNA is degraded has 
not been previously described. Identification of endonucleolytic cleavage in Pgp2 mRNA 
adds to the list of mammalian mRNAs that are degraded by endonucleolytic pathway. Based 
on the current findings, it is not possible to determine if the cleavage sites are the result of 
one or more enzymes. Future research related to this finding can pertain to purification and 
characterization of the endoribonuclease(s) responsible for cleavage of Pgp2 mRNA.
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Chapter 5 
General Discussion
This study aimed at comparing the in vivo degradation pathway of Pgp2 mRNA, 
through identification of decay intermediates in liver tumour and normal liver. The rational 
behind the study also relates to the lack of knowledge surrounding decay mechanisms 
associated with Pgp mRNA. On a global scale, it is also related to the lack of understanding 
of mRNA decay processes within mammalian systems, especially in an animal model (Ross, 
1995). This study attempted to detect Pgp2 mRNA degradation products using the Yeast 
Poly (A) Tailing RT-PCR method. At first this method was determined to be suitable due to 
its apparent sensitivity and specificity demonstrated in in-vitro assays (see Chapter 2, 
Discussion 2.2). It became apparent however, that this method was not suitable for use in 
detection of mRNA decay intermediates in vivo because it lacked specificity (See Chapter 3, 
Discussion 3.2). A Pgp2 mRNA degradation product was identified through an alternative 
method (ligation-mediated PCR; Lee, et al. unpublished results) in both normal liver and 
liver tumours. Primer extension analysis provided insight into the decay pathway by 
confirming that the decay product identified was the result of endonucleolytic cleavage, and 
by revealing four major cleavage sites within the 2E1 portion of Pgp2 mRNA. These 
cleavage sites were identical in both normal liver and liver tumour (See Chapter 4). 
Therefore, even though this study failed to detect Pgp2 mRNA decay products using the 
Yeast Poly (A) Tailing RT-PCR method, the main objective has been accomplished. Based 
on the results of the primer extension analysis, there is no indication of differential 
endonucleolytic decay pathways present between normal liver and liver tumour. The 
increased Pgp2 mRNA stability demonstrated in liver tumours in comparison to normal liver
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(Lee et al., 1998) could be related to some other decay mechanism. Observations made here 
suggest that future studies should be directed towards examining possible differences in 
deadenylation and 3’-5’ decay. As discussed previously (see Chapter 1), there are few 
explanations and mechanisms related to mRNA stabiliy in P-glycoprotein. It is the objective 
of this chapter to identify possible areas of research that could potentially shed more light on 
the issue.
Many recent observations suggest that Pgp2 mRNA is post-transcriptionally 
regulated. It was recently demonstrated that the application of cyclohexamide (a protein 
synthesis inhibitor) significantly increased Pgp2 mRNA in all normal rat tissues. The 
increase in mRNA transcripts was mainly through post-transcriptional control as there was 
no indication of a parallel increase in transcriptional activity (Lee, 2001). It has been 
suggested that this increase in Pgp2 mRNA transcript levels is due to mRNA stability (Lee, 
2001). It has also been suggested that trans-acting factors are most likely involved in Pgp2 
mRNA stability (Lee, 2001). There are a few explanations for this suggestion. First, even 
though a change in mRNA stability has been noticed between normal liver and liver tumour, 
there has been no obvious change in Pgp2 mRNA structure (Kren et al., 1996; Lee et al., 
1998). Also, an AU-rich element at the 3’UTR of Pgp mRNA failed to exhibit destabilizing 
capability demonstrated by other AU-rich elements (Prokipcak et al., 1999). Therefore, 
investigation into the presence or absence of RNA binding proteins in normal liver and liver 
tumour would be appropriate.
The involvement of mRNA decay during aging and development has not been widely 
explored. It has been recognized that specific changes in gene expression can occur during 
aging and development (Brewer, 2002). It is widely accepted that mRNA decay processes
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contribute to the control of gene expression. In some cases, mRNA stability has been linked 
to development. For instance, it has been demonstrated in mouse albumin mRNA, that 
stability is partially dependant on development and aging. This conclusion was based on the 
identification of significant levels of albumin mRNA in fetal mouse liver and undetectable 
levels in adult liver. This suggests that mRNA turnover rate is higher in fetal liver and 
decreases during development (Tharun and Sirdeshmukh, 1995). Opposite to the results 
determined for albumin mRNA, granulocyte/macrophage colony-stimulating factor (GM- 
CSF) mRNA levels are four fold lower in activated neonatal mononuclear cells from 
umbilical cord blood, as compared to adult peripheral blood (Brewer, 2002). It has also been 
proposed that in young cells there is an equal balance of mRNA degradation and stabilization 
factors present, where as in older cells degradation factors are dominant (Brewer, 2002). 
While many details related to age-dependant changes in mRNA are currently unknown, it 
would be interesting to determine if endonucleolytic decay of Pgp2 mRNA in normal liver 
changed during development.
This study has introduced key issues related to Pgp2 mRNA that were previously 
unknown. It revealed that the endonucleolytic decay pathway of Pgp2 mRNA in normal 
liver and liver tumour appears to be the same. It also provided strong evidence for the 
involvement of endoribonucleic activity in the Pgp2 mRNA decay process in vivo. In 
conclusion, it narrowed the gap of possible explanations as to why Pgp2 mRNA is more 
stable in liver tumours than normal liver.
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